Note: Descriptions are shown in the official language in which they were submitted.
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
DETECTING MICROBIAL INFECTIONS IN WOUNDS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of United States Provisional
Application No.
62/315,565, filed March 30, 2016, the disclosure in which is incorporated
herein by reference in
its entirety and made a part hereof
TECHNICAL FIELD
[0002] Embodiments described herein generally relate to wound healing, and
in particular to
compositions, apparatuses and methods for the detection and treatment of
wounds.
BACKGROUND
[0003] In mammals, dermal injury triggers an organized complex cascade of
cellular and
biochemical events that result in a healed wound. Wound healing is a complex
dynamic process
that results in the restoration of anatomic continuity and function: an
ideally healed wound is
one that has returned to normal anatomic structure, function, and appearance.
A typical wound
heals via a model consisting of four stages - 'exudative' phase, proliferative
phase, reparative
phase and epithelial maturation (Hatz et al., Wound Healing and Wound
Management, Springer-
Verlag, Munich, 1994) or hemostatic, inflammatory, proliferative and
remodeling phase
(Nwomeh et al., Cl/n. Plast. Surg. 1998, 25, 341). The inflammatory phase is
particularly
important to the wound healing process, wherein biochemical reactions at the
wound situs
facilitate healing but also cause tissue breakdown due to production of excess
proteases.
[0004] Infection of the wound results in either a slower, or an arrested
healing process. For
example, pathogens in a wound can produce toxins (e.g., Clostridium species),
generate noxious
metabolites like ammonia that raise pH (e.g., Proteus species), activate or
produce tissue lytic
enzymes like proteases, or promote tissue invasion, thereby leading to an
increase in the size or
seriousness of the wound. In a worst case, pathogens can leave the wound and
cause sepsis.
[0005] In order to keep the chronicity of wounds in check, a variety of
assessment
techniques and/or tools are employed in the clinical and veterinary setting.
Current methods of
assessing an infected wound are based primarily on assaying for a variety of
parameters
associated with the wound. For instance, a wound may be assessed visually,
length and depth
measurements may be taken, digital photography may be used where available to
track the
visual condition and size of a wound (Krasner et al., supra). In clinical
practice, diagnosis of
infection is based on measurement of secondary parameters, such as, odor,
presence of local
pain, heat, swelling, discharge, and redness Many of these clinical
indicators, such as
inflammation and discharge have a low predictive value of infection in wounds.
In other
- 1 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
instances, the number(s) and type(s) of pathogenic flora at the wound situs
may be determined
using laboratory and/or clinical diagnostic procedures. Swabbing of a wound
followed by
microbiology testing in the hospital laboratory is an option for confirmation
of bacterial
colonization and identification of the strains associated with infection, thus
allowing for the
prescription of correct antibiotic course. However, this process is time
consuming and labor
intensive. Delay in diagnosis of infection can delay the administration of
antibiotics and may
increase the risk of developing sepsis.
[0006] One of the biggest drawbacks associated with existing clinical
diagnostics is a lag
associated with the onset of infection and the timing of detection. For
instance, positive
identification of infection using swabbing procedures often depends on
attainment of a "critical
mass" of microorganisms at the wound site and so early detection cannot be
made until a
detectable level is reached. Also, the swabs may be contaminated with the
flora of the
surrounding tissue, thereby complicating the diagnostic procedure. Other
drawbacks include,
e.g., sampling errors, delays in transport of the swabs, errors in analytical
procedures, and/or
errors in reporting. See, the review by Bowler et al., Clin Microbiol Rev.
14(2): 244-269, 2001.
[0007] There is therefore an imminent but unmet need for diagnostic
reagents and methods
that enable early diagnosis of clinical infection, preferably, which permit
clinical diagnosis prior
to manifestation of clinical symptoms of infection. There is also a need for
compositions and
methods that would assist in predicting clinical infection of a wound prior to
the manifestation
of clinical symptoms. Such a prognostic aid would allow early intervention
with suitable
treatment (e.g., antimicrobial treatment) before the wound is exacerbated and
surgery or other
drastic intervention is required to prevent further infection. Additionally,
if clinicians could
respond to wound infection as early as possible, the infection could also be
treated with minimal
antibiotic usage. This would reduce the need for hospitalization and would
reduce the risk of
secondary infections, e.g., as a result of contact with other diseased
subjects.
SUMMARY
[0008] The technology disclosed herein provides for compositions and
methods of detecting
infected and/or chronic wounds. The disclosed technology improves upon exiting
assays by:
increasing the sensitivity, precision and specificity of detection of infected
wounds; providing
for the ability of qualitative and quantitative measurements; and, increasing
the speed of
detection of infected wounds in situ and in real-time. The assays and methods
described herein
are partly based on the use of specific reagents that detect biomarkers and/or
probes which are
present in infected or chronic wounds. The detection process may involve use
of reagents that
are specific to the markers present in infected wounds but not non-infected or
non-chronic
- 2 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
wounds and the detection step may involve qualitative or quantitative
measurements of the
signal(s) that are generated when the probe is acted upon by the marker. In
embodiments
wherein the detection method involves detection of enzymes present in wounds,
the probes
comprise modified enzyme substrates that are specific to the enzyme, which
generate signals
that may be optionally amplified. This greatly improves efficiency and
specificity of detection.
Moreover, a plurality of detection probes, each specific for one or more
targets, e.g., enzymes
that are specific to the wounds, may be employed. This greatly helps to
maximize both
efficiency and accuracy of diagnostic assays while minimizing the incidence of
false positives
(e.g., due non-specific interactions and/or target redundancy). Furthermore,
the experimental
results disclosed herein confirm that the novel probes and the assay
techniques based thereon are
capable of detecting and characterizing various types of wounds. Finally, the
reagents of the
disclosed technology may be used together with therapeutic molecules such as
antibiotics,
antifungal agents, etc. to monitor and evaluate treatment and management of
chronic wounds.
[0009] Embodiments described herein are based, in part, on the discovery
that cells of the
immune system, including enzymes generated thereby, may serve as markers in
the early
diagnosis of wounds. These cells, e.g., neutrophils, are recruited at the
wound situs to combat
infection, do so by engulfing bacteria (and other pathogens) and/or
neutralizing them with
enzymes. Some enzymes are specific towards proteins (e.g., elastase, cathepsin
G), others are
specific towards cell wall components (e.g., lysozyme) and yet others mediate
protein
denaturation (e.g., NADPH oxidase, xanthine oxidase, myeloperoxidase (MPO) and
other
peroxidases). These cells, e.g., neutrophils, are generally only short-lived
and when they lyse in
the area of the infection, they release the contents of their lysosomes
including the enzymes,
which can then be detected to provide a reliable measurement of the status of
the wound.
[0010] Accordingly, various embodiments described herein utilize the
detection of enzyme
markers, which are indicative of the presence of myeloid cells, and
neutrophils in particular, in a
biological sample of interest, for example, wound tissue. Increased level or
activity of such
enzymes in the wound fluid, therefore, corresponds to a heightened bacterial
challenge and a
manifestation of disturbed host/bacteria equilibrium in favor of the invasive
bacteria.
[0011] Provided herein are embodiments of a wound dressing, devices, and
methods for
detecting an infection in a wound or a sample. One embodiment is a wound
dressing comprising
a wound contacting layer, a reagent layer comprising one or more testing
regions, wherein the
reagent layer is in fluid communication with the wound contacting layer, and
an outer layer that
overlays the reagent layer. In some embodiments, the wound contacting layer
comprises gel-
forming polymers. In further embodiments, each of the one or more testing
regions comprises
one or more of each of: back-flow trap, reagent pad, filter pad, indicator
trap, and absorbent
- 3 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
area, wherein one or more viewing windows are located either above the reagent
pad or the
indicator trap. In further embodiments, the reagent pad is in fluid
communication with the filter
pad, the filter pad is in fluid communication with the indicator trap; and the
indicator trap is in
fluid communication with the absorbent area.
[0012] In other embodiments, one or more testing regions comprises one or
more reagents
selected from the group consisting of enzyme-reactive indicators, reagents
that are sources of
peroxide, enzymes that produce colored products, pH indicators, protein
responsive reagents,
and moisture-detecting reagents. The enzyme-reactive indicators include
protein-indicator
conjugates printed, sprayed, or otherwise deposited in or on the reagent pad.
In some
embodiments, the protein-indicator conjugate has the structure of Formula (I):
A-B, wherein A
is an anchor region or moiety that helps to bind an enzyme-reactive region to
the reagent pad,
and B is the enzyme-reactive region.
[0013] In some embodiments, the enzyme-reactive region comprises a peptide
and/or an
indicator region. In further embodiments, the wound dressing comprises an
indicator region that
after having been cleaved by the target enzyme in a sample is further
transformed into a colored
species by accessory enzymes selected from a lipase, esterase, hexosaminidase,
peroxidase,
oxidase, galactosidase, glycosidase, glucosidase, and laccase, or a
combination of two or more
thereof. In some embodiments, the enzyme-reactive indicators interact with
elastase, lysozyme,
cathepsin G, myeloperoxidase, or any combination thereof. In further
embodiments, the
enzyme-reactive indicators comprise a moiety capable of producing a visible
color or a
detectable electronic change upon interaction of the enzyme-labile or enzyme-
reactive region
with one or more enzymes, wherein the moiety is selected from the group
consisting of a
peroxidase substrate, arylamine, an amino phenol, a neutral dye, a charged
dye, a nanoparticle, a
colloidal gold particle, or an analog thereof. The anchor region can be
attached to the reagent
pad covalently, non-covalently, or ionically. In some embodiments, pH-
sensitive reagents
produce a visible color comprise bromothymol blue, phenol red, bromophenol
red, chlorophenol
red, thymol blue, bromocresol green, bromocresol purple; nitrazine yellow; or
other
sulfophthalein dyes.
[0014] In some embodiments, the wound dressing also comprises one or more
lines of
wicking stitching or wicking tufting throughout all layers of the wound
dressing except the outer
layer, wherein the wicking stitching or wicking tufting provides fluid
communication between
the reagent layer and the wound contacting layer. Fibers that are wettable and
exhibit capillary
action may be used for wicking stitching or wicking tufting to form fluid
communication
between a sample or a wound and the reagents. In some embodiments, the wicking
fibers are
- 4 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
solid or hollow. Examples of wicking fibers include, but are not limited to,
cotton, rayon,
viscose, wool, silk, polyester, polyamide, CMC, and polypropylene.
[0015] In further embodiments, the wound dressing comprises one or more
testing regions,
comprising a leach-back trap in fluid communication with the reagent pad and
one or more lines
of wicking stitching or wicking tufting crossing through one or more testing
regions only at the
leach-back trap. In some embodiments, a foam layer is added between the wound
contacting
layer and the reagent layer. One or more perforations can be added in the
wound contacting
layer or in the foam layer and the wound contacting layer. In further
embodiments, each of the
one or more testing regions further comprises a leach-back trap in fluid
communication with the
reagent pad and one or more perforations aligned with the leach-back trap.
[0016] In some embodiments, the testing regions comprise a multichannel
testing region,
wherein each channel within the multichannel testing region is separated from
an adjacent
channel by one or more impermeable separators or borders. Such multichannel
testing regions
can comprise 1 to 10 testing regions, preferably 3, 4, or 5 testing regions,
wherein the testing
regions are arranged in a linear or a radial configuration. Arrays of
multichannel testing regions
can be combined to cover a broader area of a wound or wound dressing. In
further
embodiments, the outer layer of the wound dressing comprises one or more
windows that permit
visualization of a signal from the reagent layer, wherein the signal is a
color change.
[0017] Such wound dressing or device provides a method of detecting the
level of one or
more enzymes in a mammalian wound, comprising contacting the mammalian wound
with the
wound dressing; observing one or more signals in the reagent layer, wherein
the signal is a color
change; and comparing the signal to a reference or control to determine the
level of an enzyme.
In another embodiment, the wound dressing can be used to detect the presence
of one or more
enzymes and/or pH in a mammalian wound, comprising contacting the mammalian
wound with
the wound dressing and observing one or more signals in the reagent layer,
wherein the signal is
a color change. In another embodiment, the wound dressing can be used to treat
an infection in
a wound of a mammal or to determine when such treatment is necessary,
comprising contacting
the wound with a wound dressing described herein, observing one or more
signals in the reagent
layer, wherein the signal is a color change and indicates the presence of an
infection, and
administering a medical treatment to the mammal.
[0018] In some embodiments, a device for detecting an infection in a wound
comprises a
wound contacting layer, a reaction layer comprising one or more reagents that
can indicate the
presence of one or more analytes associated with an infection, wherein the
reagents are affixed
to a solid phase and produce a detectable signal in a reporter area, a cover
on top of the reaction
layer, wherein the cover comprises one or more windows or clear areas to allow
visualization of
- 5 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
the detectable signal, such as a color change, and fluid communication between
the wound
contacting layer and the reaction layer. Reagents include enzyme-reactive
indicators that
interact with one or more enzymes selected from the group consisting of
lysozyme, MPO,
cathepsin G, elastase, catalase, lipase, esterase, and any combination
thereof, at least one
indicator for pH or a change in pH, wherein the indicators may be printed,
sprayed, or deposited
on a solid phase or support material, including paper, viscose, regenerated
cellulose, glass fiber,
or similar materials. In further embodiments, the enzyme-reactive indicators
comprise a moiety
capable of producing a visible color or a detectable electronic change upon
interaction of the
enzyme-labile or enzyme-reactive region with one or more enzymes, wherein the
moiety is
selected from the group consisting of a peroxidase substrate, arylamine, an
amino phenol, a
neutral dye, a charged dye, a nanoparticle, a colloidal gold particle, and an
analog thereof. In
further embodiments, the device comprises wicking stitching or wicking tufting
of an absorbent
material to form fluid communication between the wound contacting layer and
the reaction
layer.
[0019] A device for detection of infection associated enzymes that is
provided as an
independent entity and can be placed into any dressing or bandage system,
comprising a sample
inlet in fluid communication with reagent cells, wherein reagent cells
comprise indicators for
sample delivery and/or pH change, which can be one and the same, and one or
more indicators
for biomarkers of an infection, including lysozyme, MPO, cathepsin G,
elastase, catalase, lipase,
esterase, and any combination thereof. The fluid communication comprises at
least one
indicator channel, lane, or arm, such as one to ten indicator channels, or
one, two, three, four,
five, six, seven, eight, nine, or ten separate indicator channels, wherein the
indicators are printed,
sprayed, or deposited in a reaction area or field on a carrier material or
solid phase and arranged
in a radial configuration to form a disk, and wherein the reaction areas or
fields are separated by
impermeable separators or lanes. The carrier material may comprise a non-woven
material. In
some embodiments, the disk comprises reagents printed, sprayed, or deposited
on the top surface
of the disk with a trap material and a substrate material on the bottom
surface, wherein the
substrate can be digested by one or more enzymes in the sample to release one
or more products
that migrate towards the trap. In further embodiments, one or more products
are colored or
produce a color change capable of being visualized on the top surface of the
disk.
[0020] In additional embodiments, a diagnostic disk for detecting an
infection in a wound
comprises a reaction layer comprising one or more reagents that interact with
an enzyme
indicative of an infection, wherein the reagents are affixed to a solid phase;
each reagent is
sprayed, printed, or deposited in a reagent area separated by impermeable
separators; each lane
comprises a reporter area wherein a color change can be observed; and a cover
comprising a
- 6 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
window for visualizing the color change in the reported area. The diagnostic
disk may further
comprise at least one reagent that produces a color change in response to a
change in pH.
Multiple lanes in the diagnostic disk, wherein each lane contains a different
indicator/reagent,
can be arranged in a linear or radial configuration about a cut access,
perforation, or wicking
material that allows fluid communication between a sample or wound contact
material and the
reagents in the reaction layer. The reagents include indicators as described
above, namely,
reagents that interact with lysozyme, MPO, cathepsin G, elastase, catalase,
lipase, or esterase. In
some embodiments, the diagnostic disk comprises a solid phase material
selected from the group
consisting of paper, viscose, regenerated cellulose, glass fiber, and similar
material In further
embodiments, the disk is attached to a non-woven carrier in a wound dressing,
wherein means
for such attachment include, but are not limited to, a continuous adhesive,
ring or annular
adhesive, welding with UV printed border, and welding with a polyethylene
component or the
non-woven carrier.
[0021] In further embodiments, the reagents describes herein may be applied
to form a
lateral flow or dipstick device for detecting an infection in a wound,
comprising one or more
reagent disks arranged in a linear configuration, wherein each reagent disk is
impregnated with a
reagent that interacts with an enzyme to produce a color change or a similar
detectable signal,
wherein one of the disks produces a color change based on pH, and wherein the
disks are affixed
to a solid phase comprising paper, viscose, regenerated cellulose, glass
fiber, or similar
materials. Reagents include enzyme-reactive indicators that produce a color
signal in the
presence of lysozyme, MPO, cathepsin G, elastase, catalase, lipase, or
esterase. In one
embodiment, each disk is separated by an impermeable border or lane.
[0022] In a further embodiment, a standalone device for detecting an
infection in a wound or
a sample comprises a housing, comprising: a sampling component for collecting
the sample; a
sample preparation chamber in fluid communication with a reaction chamber,
wherein the
sample preparation chamber receives the sample; the reaction chamber
comprising one or more
reaction cells containing reagents that interact with one or more enzymes in
the sample to
indicate the presence of an infection and/or pH of the sample; and a window or
a clear area for
visualizing a detectable signal, wherein the signal is a color change or an
electronic output. One
or more reagents interact with an enzyme selected from the group consisting of
lysozyme, MPO,
cathepsin G, elastase, catalase, lipase, and esterase to produce a detectable
signal, wherein the
signal is a color change. One or more regents produce a color change in
response to a change in
pH, a basic pH, or an acidic pH. In further embodiments, the reagents perform
the reactions in a
primarily liquid medium, wherein the reagents may be provided in tablet form
for use in the
reaction cells. In some embodiments, the reagents may be printed, sprayed, or
deposited in
- 7 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
separate reagent fields on a support material to form a panel of tests, such
as a testing strip, for
use in the reaction chamber. Support materials include paper, viscose,
regenerated cellulose,
and glass fiber. Reagent fields can be arrayed in a line along a plastic or
paper carrier strip,
which is capable of absorbing the sample in the reaction chamber, allowing the
sample to
interact with the reagents in the reaction chamber. In some embodiments, the
sampling
component comprises a swab device, or a hook or needle device adapted to
removing a sampling
thread from a wound dressing to sample the wound fluid without disturbing the
dressing.
[0023] In further embodiments, a kit for detecting an infection in a sample
comprises a
sampling component for collecting the sample; a test device comprising a
housing surrounding a
tube to define an opening in the housing for receiving the sampling component,
the housing
comprising: a diluent chamber that holds a liquid diluent; a reaction well in
liquid
communication with the tube or the sample, the reaction well holding one or
more reagents that
interacts with one or more analytes to produce a color change or similar
detectable signal; a
viewing window or reporter area wherein the color change or similar detectable
signal can be
observed; and wherein the liquid diluent flows from the sample component into
the reaction well
to mix the sample with the reagents in the reaction well. The reagents
comprise one or more
enzyme-reactive indicators and/or pH indicator, as described above. The sample
may be
obtained from a wound, a wound dressing, or a surgical site. In some
embodiments, the
sampling component is a swab device or a hook or needle device. The reagents
can be provided
in tablet form, which are dissolved upon contacting the liquid diluent and the
sample. The
reagents can also be deposited in separate fields on a testing strip to form a
panel of tests, which
can be applied in the reaction wells.
[0024] In another embodiment, the reagents are provided in liquid form for
use in the
reaction wells. The number of reaction wells is based upon the number of
analytes to be
analyzed, ranging from one to ten, including indicators that produce a
detectable signal in
response to pH or the presence of one of the following enzymes: lysozyme, WO,
cathepsin G,
elastase, catalase, lipase, and esterase. The reaction wells can be arranged
in various
configurations, including a linear or a radial configuration.
[0025] In another embodiment, a wound dressing is disclosed comprising: a
wound
contacting layer; a reagent layer comprising one or more testing regions,
wherein the reagent
layer is in fluid communication with the wound contacting layer; and an outer
layer that overlays
the reagent layer.
[0026] In another embodiment, a wound dressing is disclosed wherein each of
the one or
more testing regions comprises one or more of each of a back-flow trap, a
reagent pad, a filter
- 8 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
pad, an indicator trap, and an absorbent area, and wherein one or more viewing
windows are
located either above the reagent pad or the indicator trap.
[0027] In another embodiment, a method of detecting the level of one or
more enzymes in a
mammalian wound is disclosed, the method comprising: contacting the mammalian
wound with
a wound dressing; observing one or more signals in the reagent layer, wherein
the signal is a
color change, a fluorescent signal, a luminescent signal, or an electrical
change, and comparing
the signal to a reference or a control to determine the level of an enzyme.
[0028] In another embodiment, a method of detecting the presence of one or
more enzymes
in a mammalian wound is disclosed, the method comprising contacting the
mammalian wound
with a wound dressing; and observing one or more signals in the reagent layer,
wherein the
signal is a color change, a fluorescent signal, a luminescent signal, or an
electrical change.
[0029] In another embodiment, a method of detecting an infection in a
mammalian wound is
disclosed, the method comprising: contacting the wound with a wound dressing;
and, observing
one or more signals in the reagent layer, wherein the signal is a color
change, a fluorescent
signal, a luminescent signal, or an electrical change.
[0030] In another embodiment, a device for detecting an infection in a
wound is disclosed,
comprising: a wound contacting layer; a reaction layer comprising one or more
reagents that can
indicate the presence of one or more analytes associated with an infection,
wherein the reagents
are affixed to a solid phase and produce a detectable signal in a reporter
area; a cover on top of
the reaction layer, wherein the cover comprises one or more windows or clear
areas to allow
visualization of the detectable signal; and, fluid communication between the
wound contacting
layer and the reaction layer.
[0031] In another embodiment, a wound dressing is disclosed wherein the
reagent pad is in
fluid communication with the filter pad; the filter pad is in fluid
communication with the
indicator trap; and the indicator trap is in fluid communication with the
absorbent area.
[0032] In another embodiment, a diagnostic disk for detecting an infection
in a wound is
disclosed, comprising: a reaction layer comprising one or more reagents that
interact with a
target enzyme indicative of an infection, wherein the reagents are affixed to
a solid phase; each
reagent is sprayed, printed, or deposited in a reagent area in a lane
separated from adjacent lanes
by impermeable separators; each lane comprises a reporter area wherein a
color, color change,
or other detectable signal is observed; and a cover comprising a window for
visualizing the
signal in the reporter area.
[0033] In another embodiment, a lateral flow or dipstick device for
detecting an infection in
a wound is disclosed, comprising: one or more reagent disks arranged in a
linear configuration,
wherein each reagent disk is impregnated with a reagent that interacts with an
enzyme to
- 9 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
produce a color change and/or is pH-sensitive, comprising bromothymol blue,
phenol red,
bromophenol red, chlorophenol red, thymol blue, bromocresol green, bromocresol
purple;
nitrazine yellow; or other sulfophthalein dyes, and wherein the disks are
affixed to a solid phase.
[0034] In another embodiment, a device for detecting an infection in a
wound or a sample is
disclosed, comprising a housing, wherein the housing comprises: a sampling
component for
collecting the sample; a sample preparation chamber in fluid communication
with a reaction
chamber, wherein the sample preparation chamber receives the sample; the
reaction chamber
comprising one or more reaction cells containing reagents that interact with
one or more
enzymes in the sample to indicate the presence of an infection and/or pH of
the sample; and a
window or a clear area for visualizing a detectable signal, wherein the signal
is a color change.
[0035] In another embodiment, a kit for detecting an infection in a sample
is disclosed,
comprising: a sampling component for collecting the sample; a test device
comprising a housing
surrounding a tube to define an opening in the housing for receiving the
sampling component,
the housing comprising: a diluent chamber that holds a liquid diluent; a
reaction well in liquid
communication with the tube, wherein the reaction well holds one or more
reagents that interact
with one or more analytes to produce a color change or a detectable signal; a
viewing window or
reporter area wherein the color change or detectable signal can be observed;
and wherein the
liquid diluent flows from the sample component into the reaction well to mix
the sample with
the reagents in the reaction well.
[0036] It is understood that other embodiments and configurations of the
subject technology
will become readily apparent to those skilled in the art from the following
detailed description,
wherein various configurations of the subject technology are shown and
described by way of
example or illustration. As will be realized, the subject technology is
capable of other and
different configurations and its several details are capable of modification
in various other
respects, all without departing from the scope of the subject technology.
Accordingly, the
figures and detailed description are to be regarded as illustrative in nature
and not as restrictive.
INCORPORATION BY REFERENCE
[0037] All publications, patents, and patent applications mentioned in this
specification are
herein incorporated by reference to the same extent as if each individual
publication, patent, or
patent application was specifically and individually indicated to be
incorporated by reference.
BRIEF DESCRIPTION OF THE FIGURES
[0038] To understand the present disclosure, it will now be described by
way of example,
with reference to the accompanying figures in which embodiments and examples
of the
- 10 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
disclosures are illustrated and, together with the descriptions below, serve
to explain the
principles of the disclosure.
[0039] FIG. 1: Examples of engineered three-dimensional fabric structures,
such as
corrugations.
[0040] FIG. 2: Example of a dressing with AQUACEL showing different layers
of a
dressing and stitching that draws fluid from a wound to the reaction layer of
the dressing.
[0041] FIG. 3: Schematic of reaction cells showing different components of
a reaction cell
with stitching (21) in (A) and cut access (27) in (B). In some embodiments,
each reaction cell
can be a different reporter or dye system.
[0042] FIG. 4: Movement of indicators in reaction cells upon exposure to
fluid, which flows
from cut access and reagents (22) toward absorbent or evaporation area (25).
Over time, the
reaction products diffuse and migrate toward an absorbent or evaporation area.
Movement of
indicators arranged in a radial manner is shown in (B). In some embodiments,
each lane or
reaction cell can be a different reporter or color system. Multiple reaction
cells can be used as
shown in (C). Multiple reaction cells can be used in arrays or combinations to
provide indicator
function over an area. Leach back traps may be used to prevent backflow.
[0043] FIG. 5: Indicators can be arranged in a circular or radial manner to
form indicator
disks (A). In some embodiments, each lane or reaction cell (45-48) can be a
different reporter or
color system, such as bromothymol blue, phenol red, bromophenol red,
chlorophenol red,
thymol blue, bromocresol green, bromocresol purple; nitrazine yellow; or other
sulfophthalein
dyes. (B) shows views of a radial indicator disk from above and from below.
[0044] FIG. 6: Dressing printed for MPO detection. In one embodiment, a
wound contact
material is sprayed or printed with amylase, starch, and glucose oxidase,
followed by printing of
a substrate for MPO printed in the centers of each sprayed area.
[0045] FIG. 7: In-place color development of MPO and elastase substrates on
testing strips
are shown. These test strips represent prototypes of visualization methods for
detecting the
presence of MPO and elastase in a sample, wherein color (e.g., blue) increases
in intensity with
greater substrate concentration.
[0046] FIG. 8: Examples of substrates, including MPO substrate (Fast Blue
derivative),
elastase substrate, and oxidation of indoxyl to blue colored indigo are shown.
[0047] FIG. 9: In-place color development of different indicators in radial
arrangement. (A)
and (B) represent prototypes of indicators for detecting certain analytes,
including pH change,
MPO, lysozyme, and elastase. In one embodiment, pH change can be reported as a
color change
from yellow to green; MPO reported as an appearance of a blue color; lysozyme
reported as an
-11-
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
appearance of pink or red color; elastase reported as an appearance of green
or blue color; and
liquid control reported as an appearance of a blue or purple color.
[0048] FIG. 10: Schematics of a radial indicator insert or disk.
[0049] FIG. 11: Schematics of a radial indicator insert or disk with a
window for detection.
[0050] FIG. 12: Schematics of another embodiment of a radial indicator
insert or disk with a
window for detection.
[0051] FIG. 13: Transport of Remazol Brilliant Blue, showing migration of
indicators to
reporter area after liquid transport.
[0052] FIG. 14: Example of a pH indicator. In one embodiment, the color can
change from
green to blue with increase in pH.
[0053] FIG. 15: Schematic of a lysozyme test strip. Fluid flow causing
stained
peptidoglycan particles to move upwards to trap layer.
[0054] FIG. 16: Examples of indicator substrates and reactions.
[0055] FIG. 17: Example of indicator disk freely placed in a dressing.
[0056] FIG. 18: Embodiments of diagnostic disks in non-woven layer in
dressing.
[0057] FIG. 19: Embodiments of diagnostic disks in non-woven layer in
dressing.
[0058] FIG. 20: Example of manufacturing diagnostic disks in sheets.
[0059] FIG. 21: Embodiments of printed and applied paper disks. In some
embodiments,
each disk can be a different reporter or color system.
[0060] FIG. 22: Methods of attaching or applying diagnostic disks to non-
woven layer in
dressing.
[0061] FIG. 23: Dipstick devices with indicator inserts or disks arranged
in different arrays
and combinations are shown. In some embodiments, each insert, disk, or lane
can be a different
reporter or color system.
[0062] FIG. 24: Sampling thread and use in dressing. Sampling thread can be
incorporated
in a wound dressing or at a surgical site, wherein the thread can be pulled
out without disturbing
the dressing to test for the presence of microbial infection or condition of
the surgical site or
wound in a diagnostic device.
[0063] FIG. 25: Assembly for manufacturing indicator inserts.
[0064] FIG. 26: Cross section of a standalone device kit
[0065] FIG. 27: Sampling tip inserted in the housing of standalone device
kit
[0066] FIG. 28: A plan view of the standalone device kit
[0067] FIG. 29: Another view of the standalone device kit
[0068] FIG. 30: A plan view of the standalone device kit with housing slid
apart
[0069] FIG. 31: Diluent chamber, tube and reaction chamber in standalone
device kit
- 12 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
[0070] FIG. 32: Distribution of test solution to each reaction chamber in
standalone device
kit
[0071] FIG. 33: Diagnostic swab device with housing, wherein reaction with
indicator disks
or inserts can be observed from a viewing window in the housing.
[0072] FIG. 34: Thread hook diagnostic device, suitable for pulling out a
sampling thread
from a dressing for analysis.
[0073] FIG. 35: Swab diagnostic device, wherein a swab is used to obtain a
sample for
testing with a diagnostic device, further comprising a diluent chamber, gas
outlet, and a plunger.
[0074] FIG. 36: Diluent chamber for sample preparation. A diluent chamber
comprising a
diluent is adapted for use with a swab device, a thread hook device, and
similar sample
preparation devices, comprising a resealable top and a seal or film at the
bottom, wherein
breaking the seal or film (402) allows the sample to mix with the diluent
solution, which flows
out of the diluent chamber and into a testing device comprising reaction
chambers or wells.
[0075] FIG. 37: Embodiment of diagnostic device with sampling chamber and
reaction
wells. One embodiment of a diagnostic device with reaction chambers (502)
adapted to being
connected to sampling chamber or diluent chamber (202) for receiving a sample
from a sample
preparation device (300), such as the swab device.
[0076] FIG. 38: Embodiment of diagnostic device or transfer system, wherein
the sample
chamber or diluent chamber uses a Luer-lock connector to attach to reaction
chambers for
testing a sample fluid. In one embodiment, the plunger or piston comprises a
gas outlet, hook
for holding a sample, and membrane that lets out gas as the plunger is
depressed into the diluent
chamber.
[0077] FIG. 39: Further embodiments of an analytic or diagnostic system,
wherein reaction
chambers are arranged in a radial arrangement.
DETAILED DESCRIPTION
[0078] Various aspects of the disclosed technology will be described more
fully hereinafter.
Such aspects may, however, be embodied in many different forms and should not
be construed
as limited to the embodiments set forth herein; rather, these embodiments are
provided so that
this disclosure will be thorough and complete, and will fully convey its scope
to those skilled in
the art.
[0079] Throughout this disclosure, various patents, patent applications and
publications are
referenced. The disclosures of these patents, patent applications and
publications in their
entireties are incorporated into this disclosure by reference in order to more
fully describe the
state of the art as known to those skilled therein as of the date of this
disclosure. This disclosure
- 13 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
will govern in the instance that there is any inconsistency between the
patents, patent
applications and publications cited and this disclosure.
[0080] Provided herein are means to detect infections in wounds. In some
embodiments
these are wound dressings able to detect infection in one or more body fluids
before such
infection is otherwise apparent. In some embodiments, the wound dressing
reacts with wound
exudate or wound fluid to detect infection in a wound through a visible or
otherwise detectable
change in the dressing. In some embodiments, wound exudate or wound fluid is
drawn up
through the wound dressing to a reagent layer for assessment of possible
infection without the
need to remove the dressing. In some embodiments, wound exudate or wound fluid
reacts with
the reagent layer to give rise to a color or other visible or observable
marker. In some
embodiments, the color is easily distinguishable from those colors that are
common in wounds
or body fluids. In some embodiments, the reaction between the wound exudate or
wound fluid
and the reagent layer of the wound dressing occurs at ambient temperature and
within a period
of time short enough to allow timely response, such as a decision to make a
dressing change
after cleaning the wound and examining the test result and/or to administer
antiseptics or local or
systemic antibiotics. In some embodiments, the color or other visible or
observable marker
and/or the location of the color or other visible or observable marker
indicates one or more areas
of the wound that deserve closer attention and/or antisepsis. In some
embodiments, the color
change function is embedded in parts of the dressing that are only visible on
dressing change. In
further embodiments, the reagent layer that gives rise to a color change or
other visible or
observable marker is a standalone device, disk, or insert, capable of
application with any wound
dressing, at a surgical or wound site, or by itself as a dipstick-type of
device. In further
embodiments, indicator reagents are applied in a "swab sample preparation
device" or a stand-
alone device into which wound fluids are injected. In some embodiments,
indicator reagents are
printed directly on support materials, such as the various layers within a
wound dressing.
[0081] In some embodiments disclosed herein, a wound dressing comprises a
wound
contacting layer; a reagent layer comprising one or more testing regions or
indicator reagents;
and an outer layer that overlays the reagent layer. The wound dressing may
comprise one or
more testing regions, which further comprise one or more of a back-flow trap,
reagent pad, a
filter pad, an indicator trap, and an absorbent area, wherein the viewing
window is located either
above the reagent pad or the indicator trap and the reagent pad is in fluid
communication with a
filter pad; the filter pad is in fluid communication with the indicator trap;
and the indicator trap
is in fluid communication with the absorbent area.
[0082] In some embodiments, testing regions comprise one or more components
selected
from the group consisting of enzyme-reactive indicators, reagents that are
sources of peroxide,
- 14 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
enzymes that are able to transform color reactions, pH indicators, protein
responsive reagents,
and moisture-detecting reagents. Enzyme-reactive indicators may comprise
protein-indicator
conjugates.
[0083] In some embodiments, protein-indicator conjugates are deposited in
or on the reagent
pad. In some embodiments, protein-indicator conjugate has the structure of
Formula (I): A-B,
wherein: A is an anchor region for attachment to the testing region; and B is
an enzyme-reactive
region. In further embodiments, the enzyme-reactive region comprises a peptide
or an indicator
region. The anchor region may be covalently or non-covalently attached to the
reagent pad.
[0084] In further embodiments, the wound dressing comprises one or more
lines of wicking
stitching or wicking tufting throughout all layers of the wound dressing
except the outer layer.
One or more testing regions further comprises a leach-back trap in fluid
communication with the
reagent pad, the one or more lines of wicking stitching or wicking tufting
crossing through each
of the one or more testing regions only at the leach-back trap. In further
embodiments, the
wound dressing comprises a foam layer between the wound contacting layer and
the reagent
layer. In some embodiments, the wound dressing further comprises one or more
perforations of
the wound contacting layer.
[0085] In some embodiments, enzyme-labile or enzyme-reactive regions
contained therein
may interact with target enzymes including elastase, lysozyme, cathepsin G,
and
myeloperoxidase. In further embodiments, the enzyme-labile or enzyme-reactive
region
comprises a moiety capable of producing a visible color or detectable
electronic change upon
interaction of the enzyme-labile or enzyme-reactive region with one or more
target enzymes, the
moiety being selected from a peroxidase substrate, arylamine, an amino phenol,
an indoxyl, a
neutral dye, a charged dye, a nanoparticle, and a colloidal gold particle, and
an analog thereof.
In some embodiments, after the target enzyme has cleaved the indicator from
the substrate it is
further reacted by an accessory enzyme selected from a lipase, esterase,
hexosaminidase,
peroxidase, oxidase, glycosidase, glucuronidase, glucosidase, and laccase, or
a combination of
one or more thereof.
[0086] Applications of the reactive regions may include a device for
detection of infection
associated enzymes, on a solid phase such as paper, viscose, regenerated
cellulose, glass fiber,
mixtures of same or similar material, or arrayed in a line along a plastic or
paper carrier strip.
[0087] In some embodiments, reagent or indicator inserts or disks for
detection of infection
associated with certain enzymes may be provided as an independent entity and
placed into any
dressing system comprising a sample inlet, diffusion channels toward different
areas containing
reagents, an indicator for sample delivery and or an indicator of pH which may
be one in the
- 15 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
same, and one or more indicators for the following markers selected from
lysozyme, MPO,
cathepsin G, elastase, catalase, lipase, esterase.
[0088] In some embodiments, the enzyme labile region is labile to a
protease and the
polymer binding domains are selected from cellulose binding domains or are
hydrophobic
binding domains.
[0089] In some embodiments, the enzyme labile region is labile to cathepsin
or elastase.
[0090] In some embodiments, the chemical entity is selected from a small
molecule entity, a
modified oligomer, and a modified polymer.
[0091] In another aspect, provided herein is a chemical entity for the
detection of infection
in a wound, the chemical entity comprising an indicator region comprising a pH-
sensitive
moiety that presents a visible color change.
[0092] In some embodiments, the chemical entity further comprises an anchor
region
wherein the anchor region enables binding of the chemical entity to a support
material.
[0093] In some embodiments, the pH-sensitive moiety that presents a visible
color change at
alkaline pH. In some embodiments, the pH-sensitive moiety that presents a
visible color change
at neutral pH. In some embodiments, the pH-sensitive moiety that presents a
visible color
change at acidic pH.
[0094] In some instances, the pH of a wound can influence many factors of
wound healing,
such as angiogenesis, protease activity, oxygen release, and bacterial
toxicity. Chronic non-
healing wounds may have an elevated alkaline environment. As the wound
progresses towards
healing, the pH of the wound moves to neutral and then becomes acidic.
Monitoring of the pH of
the wound may provide a method to assess the condition of the wound (e.g.,
infection or no
infection) and aid in determining a wound's response to treatment.
[0095] Accordingly, in some aspect of the disclosed technology, the
chemical entity for the
detection of infection in a wound comprises an indicator region comprising a
pH-sensitive
moiety that presents a visible color change. In some embodiments, the chemical
entity further
comprises an anchor region wherein the anchor region enables binding of the
chemical entity to
a support material. In some embodiments, the pH-sensitive moiety presents a
visible color
change at alkaline pH. In some embodiments, the pH-sensitive moiety presents a
visible color
change at pH = 7.2-9.5. In some embodiments, the pH-sensitive moiety presents
a visible color
change at pH = 7.2-9Ø In some embodiments, the pH-sensitive moiety presents
a visible color
change at pH = 7.2-8.5. In some embodiments, the pH-sensitive moiety presents
a visible color
change at pH = 7.2-8Ø In some embodiments, the pH-sensitive moiety presents
a visible color
change at pH = 7.5-8.5. In some embodiments, the pH-sensitive moiety presents
a visible color
change at pH = 7.5-9Ø In some embodiments, the pH-sensitive moiety presents
a visible color
- 16 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
change at pH = 8.0-9Ø In some embodiments, the pH-sensitive moiety presents
a visible color
change at pH = 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3,
8.4, 8.5, 8.6, 8.7, 8.8, 8.9,
9.0, 9.1, 9.2, 9.3, 9.4, or 9.5, or increments thereof.
[0096] In some embodiments, the pH-sensitive moiety presents a visible
color change at
neutral pH. In some embodiments, the pH-sensitive moiety presents a visible
color change at pH
= 6.9, 7.0, or 7.1, or increments thereof
[0097] In some embodiments, the pH-sensitive moiety presents a visible
color change at
acidic pH. In some embodiments, the pH-sensitive moiety presents a visible
color change at pH
= 4.5-6.8. In some embodiments, the pH-sensitive moiety presents a visible
color change at pH
= 4.5-6.5. In some embodiments, the pH-sensitive moiety presents a visible
color change at pH
= 5.0-6.8. In some embodiments, the pH-sensitive moiety presents a visible
color change at pH
= 5.4-6.8. In some embodiments, the pH-sensitive moiety presents a visible
color change at pH
= 5.4-6.5. In some embodiments, the pH-sensitive moiety presents a visible
color change at pH
= 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9,
6.0, 6.1, 6.2, 6.3, 6.4, 6.5,
6.6, 6.7, 6.8, or 6.9, or increments thereof.
[0098] In some embodiments, the pH-sensitive moiety is bromothymol blue,
phenol red,
bromophenol red, chlorophenol red, thymol blue, bromocresol green, bromocresol
purple;
nitrazine yellow; or other sulfophthalein dyes.
[0099] Other embodiments include reagents printed on dressing or solid
support materials,
dipstick devices with indicator disks arranged in various arrays, and devices
with separate
sample preparation chamber that transfer a sample of a bodily fluid or wound
fluid to a
standalone diagnostic device that uses reagent pills, solutions, or disks in
reaction chambers for
detecting biomarkers associated with microbial detection. In further
embodiments, indicator
reagents are printed, sprayed, or overlayed on support materials, such as
dressing, wound
dressing, bandage, filter paper, and test strips.
[00100] Generally, when a pathogen encounters the human body interior, cells
react through
innate receptor systems, either to injury, toxins, or to the bacterial cell
wall. All of these
recognition events result in the recruitment of innate immune cells. These
cells are stimulated
by pathogens like bacteria to activate bacterial killing systems that are
normally present in
polymorphonuclear leukoctyes (PMNs) and are mainly enzymatic in character. The
cells engulf
bacteria and lyse them with enzymes that hydrolyze proteins (e.g., protease,
elastase, cathepsin
G) and cell walls (lysozyme), or mediate protein denaturation (NADPH oxidase,
xanthine
oxidase, myeloperoxidase (MPO)). These PMNs are generally only short lived and
will
themselves lyse in the area of the infection. When they lyse, they release the
contents of their
lysosomes including the enzymes.
- 17 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
[00101] These enzymes are, therefore, biomarkers for the presence of myeloid
cells, and
PMNs in particular. A rising level of these enzymes in the wound fluid,
therefore, corresponds
to a heightened bacterial challenge and one that is not being adequately met
by the innate
defense. The association of these enzyme levels with clinical infection has
been validated using
a clinical trial approach (Blokhuis-Arkes et al., 2015).
[00102] In addition, the pH of a wound can influence many factors of wound
healing, such as
angiogenesis, protease activity, oxygen release, and bacterial toxicity.
Chronic non-healing
wounds, and those that are infected or at risk of infection, typically have an
elevated alkaline
environment. As the wound progresses towards healing, the pH of the wound
moves to neutral
and then becomes acidic. Monitoring of the pH of the wound may provide a
method to assess
the condition of the wound (e.g., infection or no infection) and aid in
determining a wound's
response to treatment.
[00103] A typical lateral flow device utilizes the concept of lateral liquid
flow in order to
transport a given sample to the test. The benefits of lateral flow tests
include rapid results, long-
term stability and low cost to manufacture. These features make lateral flow
tests well-suited
for applications involving drug testing in urine, in particular with rapid
point of care testing in
hospitals and doctor's offices being an advantage. A test strip can be dipped
directly in the
sample which is taken in a liquid form. The sample travels up the lateral flow
strip and binds to
available antibodies, which causes a reaction that can be visually detected on
the strip. Applying
this technology to samples other than urine or blood has however been
problematic.
[00104] Early detection of markers for infection in wounds has advantages in
that treatment
of infection can be commenced before the infection becomes established and
other signs of
infection become apparent, for example, discharge from the wound, redness,
pain and
unpleasant odor. A difficulty in testing for markers in wound fluid is that
wound fluid differs
greatly in its consistency and quantity. For instance it can be scant but
viscous making the use
of a lateral flow test difficult.
[00105] Thus it would be desirable to have a single kit for collecting and
testing a sample of
fluid taken from a wound that is easy to operate and not limited by the type
or quantity of
exudate from the wound. One embodiment of the standalone device kit described
herein
mitigates the above problems in a kit which comprises a sampling component and
a test device
where the test device does not rely on a lateral flow strip to move the sample
through the device
and achieve a diagnosis.
[00106] Wound Dressing
[00107] In some embodiments, the wound dressing comprises a wound contacting
layer; a
reagent layer comprising one or more testing regions; and an outer layer that
overlays the
- 18 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
reagent layer. In some embodiments, the wound dressing further comprises a
protective
cushioning layer (for example a foam or a nonwoven layer) between the wound
contacting layer
and the reagent layer. In some embodiments, the wound dressing further
comprises one or more
lines of wicking stitching or wicking tufting throughout all layers of the
wound dressing except
the outer layer. In some embodiments, the wound dressing comprises perforation
through the
wound contacting layer, the protective cushioning layer, or a combination of
both. In some
embodiments, such perforation allows for wound fluid transfer from the wound
to the reagent
layer.
[00108] Wound Contacting Layer
[00109] When in use, the wound contacting layer of the wound dressing absorbs
wound
exudate and/or wound fluid. In some embodiments, the wound contacting layer
comprises gel-
forming polymers or hydrofiber. Gel-forming polymers include, but are not
limited to cellulose,
carboxymethylcellulose (CMC), carboxyethylcellulose, oxidized cellulose (or a
derivative
thereof), cellulose ethyl sulfonate, other chemically modified cellulose,
pectin, alginate,
chitosan, modified chitosan, hyaluronic acid, polysaccharide, or gum-derived
polymer, or any
combination thereof In some embodiments, the wound contacting layer may
comprise
polyvinylpyrrolidone, polyvinyl alcohols, polyvinyl ethers, polyurethanes,
polyacrylates,
polyacrylamides, collagen, gelatin or mixtures thereof In some embodiments,
the wound
contacting layer comprises fibers of gel-forming polymers. In some
embodiments, the wound
contacting layer comprises a nonwoven layer of gel-forming fibers.
[00110] In some embodiments, the wound contacting layer further comprises non-
gel-
forming polymers. In some embodiments, the wound contacting layer comprises
cellulose (for
example, Lyocell), modified cellulose (for example, viscose or rayon),
Polyester, silk, wool,
Nylon, Polypropylene, Elastane or mixtures thereof.
[00111] In one embodiment, the thickness of the wound contact layer is from
0.1 to lOmm, in
a preferred embodiment it is from 0.1 to 5 mm and in a still more preferred
embodiment it is
from 0.3 to 3.5mm.
[00112] Protective Cushioning Layer
[00113] In some embodiments, the protective cushioning layer provides
mechanical
protection of the wound and also assists in the management of excess exudate
by acting as a
large surface area for evaporation. In some embodiments, the protective
cushioning layer may
also serve as the material that accepts fluid exiting reagent layer or device
and may add
functionality by pulling or directing fluid through the reagent layer or
device. Suitable materials
include foams, (non-gelling) fiber fleeces, (non-gelling) nonwoven fabrics,
and engineered
three-dimensional fabric structures, such as corrugations. Examples of
engineered three-
- 19 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
dimensional fabric structures are shown at FIG. 1. Preferably, materials used
for the protective
cushioning layer possess mechanical cushioning properties that are unaffected
or are minimally
affected by contact with wound exudate. In some embodiments, the protective
cushioning layer
comprises plastics based on olefins or olefin derived polymers, such as
polyethylene,
polypropylene, nylon, polyurethane, polystyrene and polyvinyl chloride. In
some embodiments,
these materials may further comprise agents such as surfactants or absorbents
that improve their
wettability.
[00114] In some embodiments, hydrophilic polyurethane foam is 2.5mm (+/-
0.5mm) thick,
with a density of 90 kg/m3 to 150 kg/m3, absorption of >12 gig.
[00115] Wicking Stitching and/or Wicking Tufting
[00116] In some embodiments, the transfer of wound fluid to the reagent layer
is optimized
by fiber tufts from the wound contact layer to the reagent layer. In some
embodiments, gel
forming polymers from the wound contact layer can be used as the transport
mechanism of fluid
from the wound to reagent layer. In some embodiments, the increased
hydrophilic nature of gel
forming polymers in comparison to materials within alternate layers of the
dressing allows
enhanced wicking action to the reagent layer.
[00117] In some embodiments, yarns can be used to provide capillary action of
fluid from the
wound contact layer to the reagent layer. This can be achieved using stitching
of one or more
layers of the dressing or using tufting of yarn through one or more dressing
layers.
[00118] In some embodiments, the wicking stitching and/or wicking tufting is
selected from
various fibers that are wettable and exhibit capillary action. Such fibers
include, but are not
limited to, cotton, rayon, viscose, wool, silk, polyester, polyamide, and CMC
fibers, solid and
hollow fibers. In some embodiments, the wicking stitching comprises cotton,
polyester,
polyamide, polypropylene, or a combination thereof. In some embodiments, using
increased
number of plies or multifilament yarn, increased linear density of yarn,
and/or decreased linear
density of fiber may enhance capillary action of yarn. In some embodiments,
the wicking
stitching comprises cotton. In some embodiments, the wicking stitching
comprises polyester. In
some embodiments, the wicking stitching comprises polyamide. In some
embodiments, the
wicking tufting comprises CMC fibers. In some embodiments, the wicking occurs
across all
areas of the dressing layers. In some embodiments, the wicking is concentrated
immediately
beneath or adjacent to the reagent layer to provide focused, enhanced wicking
action and/or
reaction with the reagent layer.
[00119] In some embodiments, stitching of yarn through hydrofiber and/or foam
layer using
hydrophilic yarn provides wicking capacity. The wound fluid can be wicked up
by yarns in a
- 20 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
more direct route to the printed substrate or reaction layer. Increase in yarn
linear density may
allow more of a decrease in wicking time and/or amount of fluid required.
[00120] In some embodiments, needling of hydrofiber-foam laminate in wound
dressing
creates tufts of hydrofiber on the foam side of the dressing. Variable
parameters of needling
include punch density and penetration depth, such as 10-100 punches/cm2 at 1-
10 mm
penetration, 20-90 punches/cm2 at 2-9 mm penetration, 30-80 punches/cm2 at 3-8
mm
penetration, 40-80 punches/cm2 at 4-8 mm penetration, 50-80 punches/cm2 at 5-8
mm
penetration, 60-80 punches/cm2 at 6-8 mm penetration, 70 punches/cm2 at 6 mm
penetration.
Channels of hydrofiber are created through the foam, leading to vertical
wicking of fluid.
Hydrofiber tufts may enable quicker fluid and enzyme transfer. Type of needles
used for tufting
include felting (crown), felting (regular), and fork. In some embodiments, use
of felting needles
allowed gelling fiber tufts to be created through the foam layer without
causing a detrimental
effect on the foam or gelling fiber. Penetration depth may be 1 mm, 2 mm, 3
mm, 4 mm, 5 mm,
6 mm, 7 mm, 8 mm, 9 mm, 10 mm, 11 mm or 12 mm, or at least 6 mm, or less than
7 mm, less
than 8 mm, less than 9 mm or less than 10 mm. Preferably, penetration depth is
6 mm, which
enabled an 18% decrease in vertical wicking time at 70 p/cm2 punch density. As
punch density
increases, more hydrofiber tufts are created on the foam layer. Enhanced fluid
transfer was seen
in all punch densities at 6 mm penetration depth.
[00121] In some embodiments, stitching of yarn through hydrofiber and/or foam
layer using
hydrophilic yarn provides wicking capacity. Stitches may be about 1 mm, about
2 mm, about 3
mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 9 mm,
about 10
mm, about 11 mm, about 12 mm, about 13 mm, about 14 mm, about 15 mm, at least
about 5
mm, less than about 6 mm, less than about 7 mm, less than about 8 mm, less
than about 9 mm or
less than about 10 mm. The wound fluid can be wicked up by yarns in a more
direct route to the
printed substrate or reaction layer. Increase in yarn linear density allows
more of a decrease in
wicking time and/or amount of fluid required. Short stitches (less than 3.5
mm) do not reduce
wicking time/volume required to wick through the foam layer. Stiches may be 5
mm to allow a
reduction in wicking time by about 45%. In some embodiments, hydrofiber-foam
laminate
material with combined thickness of 4.3 mm was tested for stitching with two
types of yarn:
high wicking polyester (continuous filament) and standard polyester thread.
Three stitch lengths
were tested, including 2.5 mm, 3.5 mm, and 5.0 mm. Incorporating stiches
enhances fluid
transfer, while increasing stitch lengths reduced vertical wicking time.
[00122] Perforation
[00123] In some embodiments, the wicking action of the various layers of the
dressing, such
as the gel-forming wound contacting layer and the foam, is adequate as it is
with the factory
- 21 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
porosity and no further treatment. In other embodiments, the wicking action
can be enhanced by
fine needling to create channels that have capillary action. In some
embodiments, the needling
can occur across all areas of the dressing layers to provide generally
enhanced capillary action.
In some embodiments, the needling is concentrated immediately beneath or
adjacent to the
common entrance to the reagent layer to provide focused, enhanced capillary
action. In some
embodiments, the perforation occurs through all layers of the dressing. In
further embodiments,
the perforation occurs in the one or more layers between the wound contact
layer and the reagent
layer. In some embodiments, capillary action can be enhanced by increasing the
punch density
of the needling to produce higher number of perforations per unit area.
[00124] Perforations allow direct fluid transfer through hydrofiber and/or
foam layers to the
printed substrate layer. The larger the hole, the more fluid may be
transferred, reducing the
wicking time/volume required for the fluid to interact with the printed
substrate layer. However,
if the hole is too large, fluid handling capacity of the dressing may be
affected. Gelling fibers
swell upon hydration and may obstruct the perforation channel of the gelling
fabric.
Perforations may be formed using a hypodermic needle. At a higher density, the
vertical
wicking time can be reduced by about 28%. In some embodiments, the vertical
wicking time is
reduced by about 10%, about 15%, about 20%, about 25%, about 30%, about 35%,
about 40%,
about 45% or about 50%.
[00125] Reactive or Reagent Layer
[00126] In some embodiments, the wound contact layer, or the layer supporting
it contains a
material that reacts to wound exudates to indicate potential infection, or a
reactive layer. A
reactive layer may comprise one or more dyes and/or the reagents necessary to
support these
reactions. In one embodiment, these dyes comprise amino acids, peptides, or
proteins
conjugated to dyes with strong ionic functions, strong contrasting colors, or
the ability to form
colors, such as indoxyl/indigo. In a preferred embodiment, addressing includes
a layer within
the dressing printed with an immobile trapping material to which said dyes
bind. This layer is
optionally in the outer part of the dressing or at various levels within the
dressing such that it
may be observed without dressing change, or at dressing change.
[00127] In another preferred embodiment, the reactive layer is comprised of an
MPO
substrate, glucose oxidase and an energy source, such as glucose or starch,
and gamma-amylase.
In another embodiment, the dressing contains particles comprised of chitosan
or a derivative that
releases dyes on hydrolysis by lysozyme. These dyes may be highly charged or
otherwise
functional to allow their accumulation at sites of signal interpretation. In
yet other
embodiments, the reactive layer comprises compounds such as p-aminophenol,
ABTS
(2,2inophenol, ABTS (strate. In some embodiments, acid) diammonium salt), 3,3'-
- 22 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
diaminobenzidine, 3,4 diaminobenzoic acid, DCPIP, N,N-dimethyl-p-
phenylenediamine, o-
dianisidine, p-phenylenediamine, 4-chloro-1-naphthol, o-phenylenediamine N-(4-
aminobuty1)-
N-ethylisoluminol, 3-amino-9-ethylcarbazole, 4-aminophthalhydrazide, 5-
aminosalicylic acid,
2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid), indoxyl, indigo, Fast
Blue RR, 4-chloro-
7-nitrobenzofurazan. In some embodiments, the reactive layer comprises an
arylamine. In some
embodiments, the reactive layer comprises an amino phenol. In some
embodiments, the reactive
layer comprises an amino phenol an aminophenol ether. In some embodiments, the
reactive
layer comprises an indoxyl. In some embodiments, the reactive layer comprises
an a neutral dye.
In some embodiments, the reactive layer comprises a charged dye, e.g., a dye
selected from
remazole brilliant blue, toluidine blue, reactive black 5, remazol brilliant
blue, reactive violet 5,
and reactive orange 16, or a hydrolytic or ammonolytic derivatives thereof,
toluidine blue,
reactive black 5, or ahydrolytic or ammonolytic derivatives thereof; reactive
violet 5, or
hydrolytic or ammonolytic derivatives thereof; reactive orange 16, or
hydrolytic or ammonolytic
derivatives thereof; a dichlorotriazine-based reactive dye such as reactive
blue 4, reactive red
120, reactive blue 2, reactive green 19 and reactive brown 10. In some
embodiments, the
dichlorotriazine-based reactive dye appears black.
[00128] In particular embodiments, the reactive layer comprises compounds such
as a
reactive dye containing a sulfonylethyl-hydrogensulphate-reactive-group. In
some embodiments,
the reactive dye is reactive black 5, remazol brilliant blue, reactive violet
5 or reactive orange
16. In some embodiments, the reactive dye is reactive black 5. In some
embodiments, the
reactive dye is remazol brilliant blue. In some embodiments, the reactive dye
is reactive violet 5.
In some embodiments, the reactive dye is reactive orange 16. In some
embodiments, the reactive
dye is reactive black 5, remazol brilliant blue, or reactive violet 5. In some
embodiments, the
reactive dye is reactive black 5 or remazol brilliant blue.
[00129] In some embodiments, the reactive layer comprises a nanoparticle. In
some
embodiments, the reactive layer comprises a colloidal gold particle. In some
embodiments, the
reactive layer comprises a charged dye, an indole derivative, or a luminol
derivative. Especially,
the reactive layer comprises a dye containing a sulfonylethyl-hydrogensulphate-
reactive-group,
e.g., reactive black 5, remazol brilliant blue, reactive violet 5 or reactive
orange 16, or a
combination thereof, or a dye containing a dichlortriazine reactive-group,
e.g., reactive blue 4,
reactive red 120, reactive blue 2, reactive green 19 and reactive brown 10, or
a combination
thereof
[00130] FIG. 3 shows two embodiments of a reaction cell, comprising indicator
units or
testing regions. In (A) of FIG. 3, stitching (21) using wicking fibers helps
to draw wound or
bodily fluid from a wound toward a reagent pad (22), then through testing
regions (23 and 24)
- 23 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
and toward absorbent or evaporation area (25). In (B) of FIG. 3, a perforation
or cut access (27)
is made, such as in the reagent pad (22) to allow the flow of wound fluid from
the wound to the
reagent pad via capillary action. The reagent pad (22) may comprise reagents
that react with
microbial biomarkers in the wound fluid, such as substrates that react with
MPO (29), elastase
(30), and lysozyme (31) in the wound fluid. In some embodiments, one or more
testing regions
may comprise a sulfonic acid filter pad (23) and a quaternary amine trap (24).
In some
embodiments, one or more testing regions comprise a leach-back trap (28) and
an amine back
flow trap or filter (29). Some embodiments contain pH indicators (32) and
protein indicators
(33) that allow a user to detect a visible signal resulting from reactions
between microbial
biomarkers in the wound fluid and the reagents in the reagent pad (22).
Absorbent or
evaporation area (25) helps to draw the flow of the fluid from the reagent pad
(22) toward (25).
In a preferred embodiment, impermeable separators (26) keep adjacent testing
regions separate.
[00131] In some embodiments, the indicator trap catches reaction products
between the
wound fluid and the one or more components selected from the group consisting
of enzyme-
reactive indicators, reagents that are sources of peroxide, enzymes that are
able to transform
color reactions, pH indicators, and moisture-detecting reagents. In some
embodiments, the
indicator trap comprises a positively charged or negatively charged trap for
reaction products.
In some embodiments, the positively charged trap comprises a quaternary amine
polymer, a
mixture of secondary and tertiary amines, other amine-containing polymers, or
a combination
thereof In some embodiments, the positively charged trap comprises polyDADMAC,
or an
analog thereof In some embodiments, the negatively charged trap comprises
polymers or
reagents containing carboxy, sulfate, sulfonate, or other acidic chemical
groups. In some
embodiments, the negatively charged trap comprises styrene sulfonate. In some
embodiments,
the indicator trap comprises a total protein indicator which is eluted by
wound fluid to indicate
overall flow and capacity of the testing region. In some embodiments, the
control region
contains a substrate for a ubiquitous enzyme such as esterase or carbonic
anhydrase, or an
indicator for a ubiquitous metabolite like lactate, glucose, ammonia or lipid.
In some
embodiments, one or more testing regions comprise a sulfonic acid filter pad
and a quaternary
amine trap. In some embodiments, one or more testing regions comprise a leach-
back trap, a
sulfonic acid filter pad and a quaternary amine trap. In some embodiments,
each of the one or
testing regions is used to evaluate the presence of one or more analytes and
one or more positive
or negative control indicators. In further embodiments, the one or more
analytes is associated
with enzyme activity. In some embodiments, the enzyme is selected from one or
more of the
group consisting of elastase, lysozyme, cathepsin G, myeloperoxidase, and
leukocyte
peroxidase. In some embodiments, the enzyme is elastase. In some embodiments,
the enzyme
- 24 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
is lysozyme. In some embodiments, the enzyme is cathepsin G. In some
embodiments, the
enzyme is myeloperoxidase. In some embodiments, the enzyme is leukocyte
peroxidase.
[00132] In some embodiments, the wound dressing comprises a reagent layer
comprising one
or more testing regions. In some embodiments, the reagent layer comprises a
support material.
In some embodiments, the support material comprises a woven or non-woven
material that is
capable of being wet by a wound fluid and which displays capillary action. In
a preferred
embodiment, the capillary action is uniform in the plane of the material. In a
preferred
embodiment, the test regions are arranged in a circle so that diffusion occurs
radially when a
liquid is applied. Support material includes, but is not limited to, paper,
cellulose, cellulose
derivatives, viscose, polyamide, polyester, polyacrylate, and other similar
polymers that are
useful as fibers, and any combination thereof In some embodiments, the support
material is
cellulose-based, such as refined papers, or non-woven material containing
bonded cellulose
fibers. In some embodiments, the support material is polyamide. In some
embodiments, the
support material is polyester. In some embodiments, the support material is
polyacrylate. In
some embodiments, the role of the solid support is to adhere substrates and
provide a field in
which analyte enzymes can travel to and interact with the detector. In some
embodiments,
cellulose content aids adherence of the enzyme substrates, and a significant
cellulose or
cellulose like content is preferred.
[00133] In some embodiments, each of the one or more testing regions is
printed on or in the
support material. In some embodiments, each of the one or more testing regions
comprises an
inlet for wound fluid, an area for the wound fluid to react with reagents
(e.g., a reagent pad), an
area to observe each product of one or more reactions, and an area for the
accumulation of
excess wound fluid (e.g., an absorbent area), which is then evaporated from an
area sufficiently
large as to not block due to accumulated solutes. In some embodiments, the
evaporation zone
helps to drive pull-through of more wound fluid.
[00134] FIG. 4 shows multiple embodiments of the movement of indicators in
various
reaction cells. When testing regions in the embodiment of (A) of FIG. 4 are
exposed to wound
fluid, wound fluid flows from the reagent pad (22) to absorbent or evaporation
area (25), as
shown in the right panel of FIG. 4(A). The embodiment of (B) of FIG. 4 shows
an embodiment
of reaction cells wherein indicators are arranged in a radial arrangement, and
wherein fluid flows
outward from the center upon encountering the reagent pad. The embodiments of
(C) of FIG. 4
illustrates how multiple reaction cells can be used to cover a broader area,
with trap leach-back
(41) preventing backflow. In some embodiments, each reagent cell or lane of
reagent pad (22)
may be a different reporter or color system, such as bromothymol blue, phenol
red, bromophenol
red, chlorophenol red, thymol blue, bromocresol green, bromocresol purple;
nitrazine yellow; or
- 25 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
other sulfophthalein dyes. In the presence of wound fluid, in one embodiment
reagents interact
with analytes in the wound fluid and migrate or diffuse toward the absorbent
or evaporation area
(25).
[00135] In some embodiments, reagents are used that require trapping of the
reaction product,
and, to this end, each of the one or more testing regions comprises a reagent
pad or a reagent cell
(22), a filter pad (23), an indicator trap (24), and an absorbent/evaporation
area (25). In
embodiments comprising a color change reagent, each of the one or more testing
regions
comprises a reagent pad that is also under a viewing window and an
absorbent/evaporation area.
In some further embodiments, each of the one or more testing regions comprises
a leach-back
trap which is a trap field that contains an absorbent that absorbs the
reagents and prevents their
back flow to the dressing below. In some embodiments, an outer layer overlays
the reagent
layer in order to modulate evaporation of wound fluid, the outer layer
containing one or more
windows to visualize the underlying indicator trap and/or reagent pad from one
or more testing
regions.
[00136] In some embodiments, each of the one or more testing regions detects
at least one
biomarker. In some embodiments, each of the one or more testing regions
comprises one or
more impermeable separators, wherein each of the one or more testing regions
detects more than
one biomarker. In some embodiments, the one or more impermeable separators are
printed
strips of hydrophobic non-permeable material. In some embodiments, the one or
more
impermeable separators are arranged in parallel lanes. In some embodiments,
the one or more
impermeable separators are arranged in a radial pattern. In some embodiments,
each of the one
or more testing regions detects two biomarkers. In some embodiments, each of
the one or more
testing regions detects three biomarkers. In some embodiments, each of the one
or more testing
regions detects four biomarkers. In some embodiments, each of the one or more
testing regions
detects five biomarkers. In some embodiments, each of the one or more testing
regions detects
six biomarkers. In some embodiments, each of the one or more testing regions
detects seven
biomarkers. In some embodiments, each of the one or more testing regions
detects eight
biomarkers. In some embodiments, each of the one or more testing regions
detects nine
biomarkers. In some embodiments, each of the one or more testing regions
detects ten
biomarkers. In some embodiment, each of the one or more testing regions
detects one or more
biomarkers.
[00137] FIG. 5 shows a radial arrangement of indicators or a radial indicator
patch. As
shown in (A) of FIG. 5, testing regions or reagents may be arranged in a
circular or radial
orientation. The indicator includes reagents (22), a quaternary amine trap
(24), and an absorbent
or evaporation area (25). A hole or cut access (27) in the middle of the
indicator helps to draw
- 26 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
fluid from a wound into the indicator. The fluid typically will flow from the
access (27)
outward to the evaporation area (25). When reagents (22) are exposed to wound
fluid and react
to microbial biomarkers, the resulting products migrate to amine trap (24),
allowing detection by
a user. The indicator may also have impermeable separators or lanes (26). As
shown in (B) of
FIG. 5, a top or "above" view is provided and a bottom or "below" view is
provided for a radial
indicator patch. In one embodiment, substrates may be printed as dots to allow
for greater
freedom of printing. Moisture impermeable film with adhesive on both sides
allows the radial
indicator patch to attach to foam or other support material. In some
embodiments, each reaction
cell or lane (45-48) can be a different reporter or color system, allowing
analysis of multiple
analytes on one indicator patch.
[00138] In some embodiments, each of the one or more testing regions comprises
one or more
components selected from the group consisting of enzyme-reactive indicators,
reagents that are
sources of peroxide, enzymes that are able to transform color reactions, pH
indicators, total
protein-detecting reagents, and moisture-detecting reagents. In some
embodiments, the reagents
that are sources of peroxide are selected from peroxy acids, sodium
percarbonate, and peroxide-
generating oxidases, such as glucose oxidase or lactate oxidase. In some
embodiments, the
enzymes that are able to assist the transformation of color reactions are
selected from
peroxidases and laccases. In some embodiments, one or more components are
immobilized
within the one or more testing regions. In some embodiments, one or more
components are
mobilized by wound fluid within the one or more testing regions. In some
embodiments, one or
more components bind to the one or more testing regions due to interaction
with wound fluid.
In further embodiments, each of the one or more testing regions further
comprises one or more
of the group consisting of buffers, binders, and solubility enhancers. In some
embodiments, one
or more buffers, binders, and/or solubility enhancers improves printing or
stability.
[00139] In some embodiments, each of the one or more testing regions comprises
an enzyme-
reactive indicator, further comprising an enzyme-labile or enzyme-reactive
moiety, an
immobilizing moiety that holds the reactive indicator in place, and a moiety
that gives rise to a
visible change upon interaction of the reactive indicator with a target
enzyme. In some
embodiments, each moiety is distinctly different from the other. In some
embodiments, one
moiety incorporates another moiety either partially or entirely. In some
embodiments, the
reagent pad comprises one or more enzyme-reactive indicators.
[00140] In some embodiments, the enzyme-reactive indicator is a protein-
indicator conjugate
such as a protease substrate comprising both protein and dye materials. In a
preferred
embodiment, the protein-indicator conjugate is a protein with a binding
function to a solid
- 27 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
phase, such as a cellulose binding domain conjugated with a protease
recognition site and dyes
that are released upon proteolysis.
[00141] In some embodiments, the pH indicator presents a visible color change
at alkaline
pH. In some embodiments, the pH indicator presents a visible color change at
pH = 7.2-9.5. In
some embodiments, the pH indicator presents a visible color change at pH = 7.2-
9Ø In some
embodiments, the pH indicator presents a visible color change at pH = 7.2-8.5.
In some
embodiments, the pH indicator presents a visible color change at pH = 7.2-8Ø
In some
embodiments, the pH indicator presents a visible color change at pH = 7.5-8.5.
In some
embodiments, the pH indicator presents a visible color change at pH = 7.5-9Ø
In some
embodiments, the pH indicator presents a visible color change at pH = 8.0-9Ø
In some
embodiments, the pH indicator presents a visible color change at pH = 7.2,
7.3, 7.4, 7.5, 7.6, 7.7,
7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2,
9.3, 9.4, or 9.5, or increments
thereof.
[00142] In some embodiments, the pH indicator presents a visible color change
at neutral pH.
In some embodiments, the pH indicator presents a visible color change at pH =
6.9, 7.0, or 7.1,
or increments thereof.
[00143] In some embodiments, the pH indicator presents a visible color change
at acidic pH.
In some embodiments, the pH indicator presents a visible color change at pH =
4.5-6.8. In some
embodiments, the pH indicator presents a visible color change at pH = 4.5-6.5.
In some
embodiments, the pH indicator presents a visible color change at pH = 5.0-6.8.
In some
embodiments, the pH indicator presents a visible color change at pH = 5.4-6.8.
In some
embodiments, the pH indicator presents a visible color change at pH = 5.4-6.5.
In some
embodiments, the pH indicator presents a visible color change at pH = 4.5,
4.6, 4.7, 4.8, 4.9, 5.0,
5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5,
6.6, 6.7, 6.8, or 6.9, or
increments thereof.
[00144] In some embodiments, the pH indicator is nitrazine yellow, bromocresol
purple or
bromothymol blue or an analog thereof.
[00145] In some embodiments, the filter pad removes unwanted components of
wound fluid,
such as fibrinogen, albumins or globulins, and cellular components or non-
cellular debris, i.e.,
dressing components, medicaments, metabolites, microbes, microbial debris,
microbial
metabolites, etc. In some embodiments, the leach-back trap prevents backflow
of reagents in the
reagent pad or reagent cell from entering the inlet for wound fluid in the
testing region. In some
embodiments, the filter pad and/or leach-back trap comprises a quaternary
amine polymer, a
mixture of secondary and tertiary amines, other amine-containing polymers, or
a combination
thereof In some embodiments, the filter pad and/or leach-back trap comprises a
quaternary
- 28 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
amine polymer. In some embodiments, the filter pad and/or leach-back trap
comprises a mixture
of secondary and tertiary amines. In some embodiments, the quaternary amine
polymer is
polydiallyldimethylammonium chloride (polyDADMAC or polyDDA). In some
embodiments,
the mixture of secondary and tertiary amines is polyethylenimine (PEI). In
some embodiments,
the filter pad and/or leach-back trap is held in place by cross-linking with
bifunctional reagents,
such as epichlorhydrin, diglycidylethers, di-epoxides or
arylazideisothiocyanates. In some
embodiments, such reagents when mixed with a reactive amine-containing polymer
link
different polymer chains and trap the longer polyDADMAC chains within a
matrix. In some
embodiments, the trap is composed of choline acrylate derivatives polymerized
in situ using a
radical initiator such as benzphenone. In some embodiments, the filter pad
and/or leach-back
trap comprises polymers or reagents containing carboxy, sulfate, sulfonate, or
other acidic
chemical groups. In some embodiments, the filter pad and/or leach-back trap
comprises styrene
sulfonate.
[00146] In some embodiments, the indicator trap catches reaction products
between the
wound fluid and the one or more components selected from the group consisting
of enzyme-
reactive indicators, reagents that are sources of peroxide, enzymes that are
able to transform
color reactions, pH indicators, and moisture-detecting reagents. In some
embodiments, the
indicator trap comprises a positively charged or negatively charged trap for
reaction products.
In some embodiments, the positively charged trap comprises a quaternary amine
polymer, a
mixture of secondary and tertiary amines, other amine-containing polymers, or
a combination
thereof. In some embodiments, the positively charged trap comprises
polyDADMAC, or an
analog thereof. In some embodiments, the negatively charged trap comprises
polymers or
reagents containing carboxy, sulfate, sulfonate, or other acidic chemical
groups. In some
embodiments, the negatively charged trap comprises styrene sulfonate. In some
embodiments,
styrene sulfonate is diluted to 0.02 to 0.8% in water and printed in this form
to the support
material. In yet other embodiments, styrene sulfonate is diluted to between
about 0.01% to 2.0%,
about 0.01% to 1.5%, about 0.01% to 1%, about 0.05% to 1%, about 0.1% to 1% or
about 0.5%
to 1%.
[00147] In some embodiments, the indicator trap comprises a total protein
indicator which is
eluted by wound fluid to indicate overall flow and capacity of the testing
region. This region is
distinct from the moisture indicator. In one embodiment, a blue polysulfonate
dye, such as
Evans or Trypan blue, is weakly bound to a tertiary amine trap. On arrival of
protein, the dye is
displaced and re-trapped as a Protein complex on a quaternary amine trap. In
another
embodiment, Coomassie Blue G250 is weakly bound to a Styrene sulfonate field
and is
displaced by protein to be re-trapped on a quaternary amine trap. The dye
undergoes a mild
- 29 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
color change from the sulfonic acid environment to the amine environment
increasing the effect.
In another embodiment, the visualization field is pre-printed with the Ponceau
S complex of the
quaternary amine trap such that it is red indicating non-function. The
conversion of the trap to
the Blue form indicates the progress of protein elution.
[00148] In an embodiment of an indicator of the arrival of fluid in the
system, Brilliant Black
or a similar dark tetra sulfonate is printed into a reagent pad as a free
reagent without any
polymer complexing. Being water soluble, it is readily mobilized by the wound
fluid and
migrates to the window where it is avidly trapped by a quaternary amine trap.
The high
polysulfonation increases the avidity for the amine and resists further
elution by proteins. Under
conditions of high secretion, the eventual removal of the dye from the trap
may also serve to
indicate exhaustion of the device or a need to change it.
[00149] In some embodiments, one or more testing regions comprise a sulfonic
acid filter pad
and a quaternary amine trap. In some embodiments, one or more testing regions
comprise a
leach-back trap, a sulfonic acid filter pad and a quaternary amine trap.
[00150] In some embodiments, each of the one or testing regions is used to
evaluate the
presence of one or more analytes and one or more positive or negative control
indicators. In
some embodiments, the one or more analytes is associated with enzyme activity.
In some
embodiments, the enzyme is selected from one or more of the group consisting
of elastase,
lysozyme, cathepsin G, myeloperoxidase, and leukocyte peroxidase. In some
embodiments, the
enzyme is elastase. In some embodiments, the enzyme is lysozyme. In some
embodiments, the
enzyme is cathepsin G. In some embodiments, the enzyme is myeloperoxidase. In
some
embodiments, the enzyme is leukocyte peroxidase.
[00151] In some embodiments, a positive result (e.g., indication of infection)
from the one or
more testing regions is in the form of a visible change. In some embodiments,
the visible
change is a color. In some embodiments, the color is selected from dark blue,
dark green, and
black. It is clear to those skilled in the art that the signal effect of the
color change depends on
context and practical consideration of interfering colors from the wound
itself. Thus, red is a
useful signal to indicate a problem, or to indicate stop or not ready, but it
is readily confused
with colors associated with wound fluids. Thus, colors that are not likely to
emerge from a
wound offer potentially less source of error. In some embodiments, the visible
change is
fluorescent, luminescent, or mediated by physical means such as electrical,
refraction, gas
evolution or polymer state change. Some fluorescent systems have the drawback
that they
require a source of light and potentially a darkened room or chamber for
viewing, however,
other fluorescent systems do not have such drawbacks. Conventional colors are
visible under
normal treatment conditions. Given that a color may be diluted or covered by
fluids such as
- 30 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
blood, there remains an embodiment in which a dual indicator is used in which
a fluorescent
indicator is mixed with a conventional color indicator. Thus, if a field is
covered by blood, the
result may be optionally interrogated with a black-light to determine whether
a signal is present.
[00152] Outer Layer
[00153] In some embodiments, the outer layer comprises a polymer that is not
easily
penetrated by wound fluid. Such polymers include, but are not limited to, a
polyolefin, a
polypropylene, a polyethylene, polyurethane, polyamides, ethylene-vinyl
alcohol (EVOH),
acrylonitrile (PAN), polyvinyl choride (PVC), polyvinylidene chloride (PVDC),
polyacrylates
(e.g., (1-methyl-1,2-ethandiy1)bis[oxy(methyl-2,1-ethandiy1) diacrylate) or
other similar
hydrophobic impermeable polymers that, in some embodiments, are laid down as
films by
printing, spraying or film blowing. In some embodiments, the outer layer is
water vapor
permeable. In some embodiments, the outer layer prevents moisture loss in
specific areas (e.g.,
where a visible change indicating infection is observed) and promotes moisture
loss in other
specific areas (e.g., where excess wound fluid accumulates).
[00154] In some embodiments, the reaction layer is protected by two layers: a
top layer and a
bottom layer. The bottom layer typically has an opening that allows fluid
sample inflow. The
top layer generally prevents premature evaporation of the sample and may force
it to migrate
through the device to the evaporation zone. The top layer may also contain one
or more
windows that allow the response of the reagents to be seen or detected.
[00155] Devices
[00156] In yet other embodiments, the disclosure herein provides a device
comprising a
sampling component and a test device comprising:
[00157] (a) a housing surrounding a tube to define an opening in the housing
to receive the
sampling component, the housing also having disposed within it:
[00158] (b) a sealed diluent chamber connected to the tube and holding a
liquid diluent for
removing the sample from the sampling tip to form a liquid test sample;
[00159] (c) a reaction well in liquid communication with the tube, the
reaction well holding a
reagent capable of indicating the presence of the analyte within the test
liquid; and
[00160] (d) a forcing mechanism capable of moving the diluent through the
device from the
chamber, over the sample tip and into the reaction well.
[00161] In some embodiments, the device operates by driving the diluent over
the sample and
into a reaction well, and a test solution is made by the flow of the diluent
over the sample.
Preferably, it is not necessary to first mix the sample with the diluent to
make a test solution and
then move that solution via a lateral flow strip to the reaction well. The
moving of the diluent
past the sample and to the reaction well means that the kit can be used with a
minimum number
-31 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
of steps, for instance taking the sample, inserting the sampling component
into the housing and
activating the moving or driving mechanism. This procedure minimizes user
error and thus
minimizes false-negative results and misdiagnoses.
[00162] In some embodiments, the diluent is forced through the device in a one-
step or multi-
step process. For instance, in a one-step process, the diluent is forced
through the device which
creates a test liquid, which is forced into the reaction well. In a multi-step
process, such as a
two-step process, the diluent could first be forced through the device to a
mixing chamber where
a test liquid is prepared. That liquid could then be forced from the mixing
chamber to the
reaction well in a further step.
[00163] In another embodiment, the means of mixing and loading the sample may
be
achieved in a separate step to its analysis. In one embodiment, a sample swab
is first inserted
into a recipient fluid container, and then a coaxial plunger is pushed over
the swab to eject
diluted sample into the analysis device. In a preferred embodiment, gas is
removed, such as by
using Goretex membranes which are gas and vapor permeable but not permeable to
liquid water.
Said membranes can be used to degas both the sample as it is injected and to
vent the fluid
chambers where the assay takes place.
[00164] In one embodiment, preferably the diluted sample is distributed to
each analysis
chamber equally through microchannels. However, when each exit from a chamber
contains a
Goretex membrane, back pressure ensures that each chamber is only filled once.
In a more
preferred embodiment, the loss of liquid sample from the assembly is prevented
by an absorbent
between the last outlet and the exterior of the device.
[00165] In still other embodiments, the disclosure herein provides a kit for
detecting an
analyte or biological marker or target in a sample comprising:
[00166] (i) a sampling component comprising a sampling tip for collecting the
sample and
[00167] (ii) a test device comprising: a housing surrounding a tube to define
an opening in the
housing to receive the sampling component, the housing also having disposed
within it: a sealed
diluent chamber connected to the tube and holding a liquid diluent for
removing the sample from
the sampling tip to form a test liquid; a reaction well in liquid
communication with the tube, the
reaction well holding a reagent capable of indicating the presence of the
analyte within the test
liquid; and a forcing mechanism capable of moving the diluent through the
device from the
chamber, over the sample tip and into the reaction well.
[00168] The sealed diluent chamber may contain a specified volume of diluent
so that an
expected volume of test solution reaches the reaction well or wells. In
addition the pathway
between the diluent chamber and the reaction well is preferably vented at the
reaction well end
so that trapped air does not affect the flow of test solution through the
device or prevent the test
- 32 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
solution from reaching the reaction well or prevent the test liquid from
correctly filling the
reaction well.
[00169] The housing preferably has two parts which are capable of moving with
respect to
each other while remaining connected to one another. The action of moving the
parts may
provide the forcing mechanism by which diluent is moved through the device.
The diluent may
be driven through the device by compression of the diluent chamber which
forces the diluent
past the sample tip and to the reaction well or wells emptying the compression
chamber. The
compression of the diluent chamber can occur when the parts of the housing are
moved with
respect to one another such as by sliding one part past another. Alternatively
the diluent can be
pulled through the device again for example by moving parts of the housing
with respect to one
another.
[00170] The sampling component preferably comprises a handle and a sampling
tip, the
handle preferably comprising a seal which engages with the opening in the
housing to seal the
tube when the sampling component is fully inserted in the tube. The seal
prevents escape of the
sample and diluent from the device reducing the chance of cross contamination
from the wound
fluid. Preferably the seal and tube engage to lock the sampling component in
the device and
prevent removal of the sampling component once it has been used. This further
reduces the
chance of cross-contamination from the sampling component. The sampling
component
preferably activates release of the diluent from the diluent chamber.
[00171] The housing may comprise a locking mechanism which locks the housing
in position
once the driving mechanism has been activated and prevents reuse of the
device. In this way it
is immediately apparent that the device has been used and cannot be used
again. This minimizes
false results from, for instance, a device that has been mistakenly activated
in transit or from
reuse of a device whose reagents have been spent.
[00172] Preferably insertion of the sampling component in the device releases
the seal on the
diluent chamber. Preferably the seal is a ball valve or can be a film or
membrane seal or a duck
bill valve or other non-return valve known in the art which is activated when
the sampling
component is inserted in the device. The sampling component preferably bursts,
punctures or
displaces the seal on the diluent chamber.
[00173] Preferably the tube is the same or similar size to the sampling tip of
the sampling
component so that the act of inserting the sampling tip into the tube causes
it to be scraped along
the walls of the tube aiding the dispersion of the sample in the diluent once
it is released from
the diluent chamber and is flushed through the device. The diluent can be
flushed along the
whole length of the tube or only part thereof. The sizing of the sampling tip
to match the tube
- 33 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
also forces the diluent to be flushed through the tip when the diluent is
driven from the diluent
chamber. Preferably the tube is wider at its mouth to aid insertion.
[00174] Preferably the diluent chamber is shaped like a bellows to assist in
the compression
of the chamber alternatively the chamber can be a combination of a plunger and
tube similar to
that found in a syringe, or sample preparation device, or can be a filled
flexible sachet which is
compressed by hand by the user or a balloon which contracts when the seal is
released.
[00175] Methods of Use
[00176] In one aspect, provided herein are methods to diagnose and indicate
need for
treatment of chronic wounds using a wound dressing described herein.
[00177] In some embodiments, the methods and devices disclosed herein detect
biological
markers or targets from body fluid. In some embodiments, the body fluid is
blood, plasma,
serum, cerebrospinal fluid, sputum, urine or wound exudate. In preferred
embodiments, the body
fluid is wound exudate.
[00178] In another aspect, provided herein are methods to diagnose chronic
wounds using a
wound dressing described herein.
[00179] In another aspect, provided herein are methods to indicate need for
treatment of
chronic wounds using a wound dressing described herein.
[00180] In another aspect, provided herein are methods to indicate need for
treatment of
surgical or acute wounds using a wound dressing described herein.
[00181] In another aspect, provided herein are methods of detecting biomarkers
of infection
in wounds using a wound dressing described herein.
[00182] In another aspect, provided herein are methods of detecting the pH
and/or the
presence of biomarkers of infection in wounds using a wound dressing described
herein. In
some embodiments, the biomarkers of infection are leukocyte enzymes. In some
embodiments,
alkaline pH in the wound indicates infection in the wound.
[00183] In another aspect, provided herein are methods of detecting protease
activity in
wounds using a wound dressing described herein.
[00184] In another aspect, provided herein are methods of monitoring the
condition of a
wound or surgical site and its healing process or status.
EXAMPLES
[00185] Example 1: Wound dressing
[00186] One example of a construction of a wound dressing incorporating the
device is
shown in FIG. 2. The wound contact layer in this example is
carboxymethylcellulose marketed
as "AQUACEL", and the AQUACEL is backed by a polyurethane foam. In the
infection-
- 34 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
indicating area of the device is an impermeable area beneath the reagent
layer. Connecting to
this area is a material such as a polyester thread, methylcellulose fibers, or
a similar wicking,
hydrophilic, capillary or similar material, or capillary channels. This fluid
connection brings
wound exudate or fluid into contact with the reagent layer, where it may react
with and mobilize
indicator reagents into visible products that are either visible in place or
trapped in window
visible from the outside of the dressing. This example also demonstrates the
use of AQUACEL.
[00187] In one embodiment of a wound dressing is shown in cross-section in
FIG. 2. In that
wound dressing the wound contact layer (4) comprises carboxymethylcellulose,
marketed as
AQUACEL. In FIG. 2, the wound contact layer (4) is backed by a polyurethane
foam (3). In
the infection-indicating area of the dressing is an impermeable area beneath
the reagent layer (2)
and above the polyurethane foam (3). Accordingly, in this embodiment the
infection-indicating
area is provided between the reagent layer (2) and the polyurethane foam (3).
Connecting to the
infection-indicating area is a fluid connection (1) component, such as a
material such as a
polyester thread, methylcellulose fibers, or a similar wicking, hydrophilic,
capillary or similar
material, or capillary channels (1). This fluid connection component (1)
brings wound fluid into
contact with the reagent layer (2), where it may react with and mobilize
indicator reagents into
visible products that are either visible in place or trapped in window (6)
visible from the outside
of the dressing as shown in the top view of the wound dressing shwon in (C) of
FIG. 2. As
explained above, views (A) and (B) of FIG. 2 show side views of the wound
dressing (7). View
(B) of FIG. 2 shows the flow of wound fluid (5) from the wound contacting
layer (4) at the
bottom upward via capillary channels (1), which may be formed by stitching
using wicking
fibers. The wound fluid reacts with reagents in reagent layer (2), which may
contain windows
(6), allowing users to observe a visible signal resulting from reactions
between wound fluid and
reagents in the wound dressing. View (C) of FIG. 2 shows a top view of a wound
dressing (7),
wherein an opaque film on top of the reagent layer (2) contains windows or
clear areas (6) that
allow the observation of indicators or changes associated with reagent
interaction with an
analyte. In some embodiments, a visible signal may be a color change
indicative of a microbial
infection in the wound.
[00188] Example 2: A dressing material printed with a patterned reactive ink
to report
MPO activity.
[00189] A dressing wound contact layer has an upper and lower surface in which
the lower
surface is the wound contact layer. Reagents can be sprayed or printed on a
wound dressing
material. One embodiment of such dressing is shown in FIG. 6, wherein (A)
depicts a view of
the surface of the wound dressing material and illustrates the topside of
wound contact material;
- 35 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
(B) represents the wound material sprayed with amylase, starch, and glucose
oxidase; and (C)
represents substrate-printed in the centers of the sprayed area.
[00190] In alternate embodiments, onto the upper surface are printed multiple
layers, such as
three layers, to report MPO activity. In one embodiment the first layer is the
substrate which is
printed on the upper surface of the wound dressing material, such as at a
concentration of 30
mg/mL in ethanol/heptane using a line width of 0.8 mm and a print density of 1
pt/cm.
Alternatively, the fast blue substrate is printed a grid of circles each 3 mm
in diameter (FIG. 6).
In one embodiment the next layer is a spray application of a solution of gamma-
amylase and
glucose oxidase immobilized on hydoxypropyl cellulose. The material may be
sprayed in a
water buffer solution such that approximately 3 [tg of glucose oxidase is
deposited per cm2, in
parallel, 0.5 g/cm2 of gamma amylase is applied as the conjugate. Once dried,
a starch
suspension may be sprayed at a density of 150 jig per cm2. Once printed, the
wound contact
layer is preferably bonded to an upper protecting layer. The same printing
regime can be printed
on the upper side an upper protecting layer. When exposed to artificial wound
fluid containing
enzymes, the grid becomes blue colored over time.
[00191] Example 3: An absorbent material printed with a patterned reactive ink
to
report elastase activity.
[00192] In this example a dressing has an absorbent and protective layer which
has an upper
and lower surface in which the lower surface contacts the wound contact layer.
Onto the upper
surface a grid pattern is printed with 1 cm grid spacing. In one embodiment,
as shown in FIG.
8, the print is performed with a solution of the AAPV-indoxyl ester 30 mg/mL
in
heptane/butanol using a line width of 1 mm and a print density of 1.3 pL/cm.
FIG. 7 illustrates
embodiments of in-place color development of MPO and elastase substrates.
[00193] Example 4: A multi-biomarker device insert
[00194] The visualization methods are preferably either a color change of an
immobile
enzyme substrate, directly printed in the window of the reporter area, or of
the appearance of an
immobilization of the substrate caused by hydrophobic properties of the
substance and non-
covalent chemical interactions with the carrier material. The amount of
applied substrate and
possible impregnation mixtures for color improvement were tested in this
example as described
below
[00195] Optimization of the reporter area and color signal: Circles (diameter
5 mm) were
punched out of carrier material, in this case filter paper. Circles were
impregnated with different
mixtures of buffers (see specific reagents : Artificial wound fluid 2 % bovine
serum albumin in
phosphate buffered saline containing potassium chloride, urea pH 7.2). See
FIG. 8 for examples
- 36 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
of substrates in a water solution followed by a drying step. After drying,
varying amounts of
substrate, usually in an organic solution, were pipetted on the test circles.
[00196] The reactivity to wound fluid was tested as follows: 10 [iL test
liquid (buffer or
artificial wound fluid 2 % albumin) with or without enzyme were pipetted on
the dried test
disks. Disks were incubated either in open air or in a closed system. Color
development was
evaluated visually at various times after initiation. All observations were at
room temperature to
simulate the condition expected outside the dressing.
[00197] After optimization of the two visualization methods, prototypes were
prepared in lab
scale to test the interaction of the different enzyme substrates/their color
development.
Prototypes were designed and assembled as described in FIGS. 7 and 9.
[00198] FIGS. 7 and 9 show embodiments of in-place color development of
different
indicators. FIG. 9 shows a prototype with the reporter areas for lysozyme,
elastase and MPO
detection, a pH indicator and the liquid control was constructed. On the left
portion in (A) the
diagnostic material is shown. On the right portion in (A) a magnification of
the reporter area is
shown. (B) shows the diagnostic area after liquid application (artificial
wound fluid 0.5 %
albumin, 1 U/mL elastase, 10 [tg/mL MPO, 30000 U/mL lysozyme). The experiment
was run
over 2 h with a flow rate of 100 4/min for the first 10 min, followed by 10
[IL/min. The
experiment was repeated in n=10.
[00199] Embodiments of diagnostic inserts or disks are shown in FIGS. 10, 11,
and 12. FIG.
10(A) shows the top view of a diagnostic insert, comprising a reporter area
(60), reaction area
(61), and evaporation area (62). FIG. 10(B) shows the bottom layer, comprising
an
impermeable layer of plastic film, either white or transparent, with a
diameter of about 40 mm.
The hole in the middle allows for liquid transport and has a diameter of about
4 mm. The
bottom layer is covered with adhesive and in the same shape underneath for an
exact fixation on
a dressing. FIG. 10 shows embodiments of the reaction material comprising an
adhesive layer
(C) and a reaction layer (D), wherein each arm has a different
substrate/indicator and/or pH
system. FIG. 10(E) shows the cover, which comprises an impermeable white
plastic foil with a
diameter of 20 mm. The outer ring may have an insider diameter of 25 mm and an
outer
diameter of 31 mm. The top layer may be covered with adhesive underneath for
an exact
fixation on the reaction material.
[00200] Top view of the assembled completed diagnostic insert. See FIG. 10(A).
The
reporter area is designed as a window surrounded by an off-white layer to
achieve a maximum
contrast to the color signals. In this embodiment, there are five radial arms,
each of which
contains a different reporter and color system. In one embodiment, three are
for enzymes and
two are for controls.
- 37 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
[00201] The evaporation area ensures a continuous liquid transport through the
diagnostic
material, necessary for the enzyme reaction and color development in the
reporter area.
[00202] Bottom layer as liquid barrier between the dressing and the diagnostic
material.
Liquid will preferably pass only through the hole in the middle of the layer
which leads to a
directed radial distribution into the arms of the reaction material
(diagnostic material).
[00203] Diagnostic material was designed with four or five radial "arms"
depending on the
favored number of enzyme-substrates and controls to be included. The reaction
material is fixed
on the bottom layer with medical adhesive. Alternatively, the reaction arms
are printed or
coated with the less permeable bottom layer in place of the adhesive (one
material can serve
both purposes).
[00204] In some embodiments, the device insert comprises at least one arm or
fewer than ten
arms. The number of arms may depend on the number of analytes to be determined
in a sample
and control(s), as applicable. In further embodiments, the device insert
comprises one, two,
three, four, five, six, seven, eight, nine, or ten arms.
[00205] The reaction material is prepared with impregnation mixtures and
substrates in
accordance to the optimized conditions described above before assembling the
detection
material.
[00206] As shown in FIG. 10(E), the cover has several functions. Firstly, it
preferably
maintains the reaction zone moist by preferably preventing premature drying.
Fluids should
pass through the reaction area into the reporter area where there is a
transparent window that
allows color changes to be seen. The second function is preferably to avoid a
stop of liquid flow
and to cover the chemistry area so that colored reagents are not seen before
they are transported
to the window. The cover is water impermeable and includes the windows for
signal
visualization.
[00207] The detection material is preferably fixed with a medical adhesive to
the foam
backing layer of a hydrofiber dressing.
[00208] Optimization of the first visualization method (accumulation and
trapping)
established the following conditions:
[00209] Trapping mixture: Volume of 1.5 p.L per 10 mm2, thickener
Methylcellulose
(Methocel A4C) max. 1.25 %. Drying at room temperature for at least 1 h.
[00210] Transport of Remazol Brilliant Blue (FIG. 13) and visualization in the
trap coated
reporter area containing the amino-trap (triplicates), test liquid was
artificial wound fluid 2 %
albumin. This visualization method was used for the Lysozyme-substrate
(results obtained by
QZY); released and trapped dye after enzyme cleavage: Remazol Brilliant Black)
and the liquid
control (dye: Brilliant Black BN).
- 38 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
[00211] FIG. 13 shows visualization of dye in reporter area (D) after exposure
of reaction
area (C) to artificial wound fluid. The direction of the fluid flow was from
reaction area (C) to
reported area (D), further comprising amino trap. The experiment was done in
triplicates.
[00212] Optimization of the second visualization method (in-place color
change) led to
clearly colored signals for the MPO-substrate, the elastase substrate and a pH
Indicator.
[00213] MPO-substrate: The MPO substrate in this example is a Fast Blue
derivative. The
substrate is soluble in 50 C ethanol. After pipetting of 1.5 [IL of a
saturated solution at the
reporter area followed by a drying step (20 min, room temperature) the
substrate cannot be
mobilized by artificial wound fluid 2 % albumin. The slightly beige MPO
substrate is converted
by MPO under development to a deep blue to black color in the reporter area.
As the MPO
reaction is H202 dependent, a glucose/glucose oxidase based H202 generating
system is printed
in the reaction area.
[00214] Optimized conditions led to the results shown in FIG. 7. Test circles
contain 1.5 iL
MPO substrate as described above, 10 lig glucose and 1 mt of 0.1 % glucose
oxidase (1 jig) in
water. After drying of the test circles 5 [IL test liquid (artificial wound
fluid 2 % albumin, pH 7,
without/with MPO) were applied. The picture of FIG. 7 was taken after 2 min
incubation time.
[00215] Elastase substrate: The elastase substrate consists of an Fmoc
protected AAPV
enzyme recognition motif (amino-acid sequence AAPV) esterified to an Indoxyl
moiety. It is
soluble in organic solvents, but completely insoluble in aqueous solution.
After enzyme
cleavage, Indoxyl is released and immediately oxidized to immobile blue Indigo
dye (FIG. 8),
visible in the reporter area.
[00216] Optimized conditions led to the result shown in FIG. 7. In a first
step, the test circles
were impregnated with a impregnation mixture (0.25 % (w/w) Nonidet, 2 % (w/w)
decanol in
0.05 M borate buffer pH 8). Therefor the two-phase solution was mixed until
formation of an
opalescent dispersion. This dispersion was transferred in a glass container.
The test circles were
washed in the impregnation mixture for 1-2 min. Thereafter the filter papers
were placed on a
glass plate and dried for 1-2 h at 54 C.
[00217] In the next step elastase-substrate (10 mg/mL in acetone) was pipetted
on the circles
2 times in 2.5 [IL steps until a final amount of 50 mg per test circle (20
mm2) was applied (FIG.
7). After drying at room temperature an elastase assay was performed by
addition of 10 [IL test
liquid (artificial wound fluid 2 % albumin, pH 7, with/without elastase).
Color development was
observed and documented after 15 min incubation at room temperature.
[00218] The pH indicator is a preparation of bromothymol blue in chitosan,
containing
glutaraldehyde. The mixture is pipetted in the reporter area, after drying
leading to a dark
yellow and immobile indicator system. The color changes from slightly green
(pH 7) to a dark
- 39 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
green (pH 8) within 30 minutes of liquid flow (artificial wound fluid 2 %
albumin). See FIG.
14 for an example of a pH indicator.
[00219] Immobilized bromothymol blue derived pH indicator after running with
approximately 300 p,L artificial wound fluid 2 % albumin with different pH
values. pH
indicator was applied in amounts of 1.5 ttL per 10 mm2 in three pipetting
steps of 0.5 pt.
[00220] Production and functionality of the reporter area in prototypes. In
the reporter areas
of the arms of the diagnostic material for Lysozyme detection and the liquid
control, 1.5 [IL of
the trapping mixture were printed. In the reporter areas for Elastase and MPO
detection as well
as for the pH indicator, the substrates were applied (FIG. 7, 9).
[00221] FIG. 9 shows a prototype with the reporter areas for lysozyme,
elastase and MPO
detection, a pH indicator and the liquid control. On the left the diagnostic
material is shown, on
the right a magnification of the reporter areas. FIG. 9 (A) shows an example
for a prototype
with the reporter areas before liquid application.
[00222] FIG. 9 displays the diagnostic area after liquid application (negative
control,
artificial wound fluid 0.5 % albumin without enzymes). FIG. 9(C) shows the
diagnostic area
after liquid application (artificial wound fluid 0.5 % albumin, 1 U/mL
elastase, 10 g/mL WO,
30000 U/mL lysozyme). The experiment was run over 2 h with a flow rate of 100
L/min for
the first 10 min, followed by 10 L/min. The experiment was repeated in n=10.
[00223] FIG. 9 shows a prototype with the reporter areas for lysozyme,
elastase and MPO
detection, a pH indicator and the liquid control. On the left the diagnostic
material is shown, on
the right a magnification of the reporter areas. Color signals for the liquid
flow control are
visible, so it is believed that the method of visualization by trapping and
accumulation works.
The order of reaction is generally MPO, then elastase, then lysozyme. Color
change of the pH
indicator as well as the color development of the MPO and elastase substrates
is visible in the
reporter area. The in-place color change was established for these reactions
and functionality
was demonstrated.
[00224] The inserts can be made in many forms including radial designs (FIG.
10-12), linear
designs and single spot approaches. These vary in which layers and patterns
are formed. It is
generally the goal to make the insert as small and non-occlusive as possible.
[00225] One means to reduce occlusiveness is to reduce the area of film
layers. In the
embodiments shown in FIG. 10-12, the only occlusive layers are the lanes
themselves. In this
version, the round bottom layer is replaced by only the adhesive. The
advantage of the round
bottom layer is that tended to support a broader area of the dressing being
sampled into the
device. The reduced bottom layer has the advantage of permitting more vapor
transfer.
- 40 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
[00226] Example 4: Lysozyme responsive testing strip
[00227] In one embodiment of a means to detect lysozyme activity, a strip of a
wicking
substance like filter paper is printed with both dyed peptidoglycan (FIG.
15(D), a) and a trap
material (quaternary amine fixed with cross-linked PEI) (FIG. 15(D), b). Wound
fluid is
applied to the base and allowed to wick up the carrier to point C where it
evaporates.
Lysozyme, if present, degrades the dyed peptidoglycan and transports anionic
fragments to the
trap (FIG. 15(D), b) where they form a line.
[00228] In FIG. 15, one embodiment of a lysozyme test strip (50) comprises a
Whatman
filter 1001/85 that is cut into 0.5 cm x 4 cm pieces having fixation areas
(51), evaporation area
(52), 3% crosslinked, amino trap (53), substrate area (54), and a stitching
area (21) for wicking
fluid from a wound. Side view (B) shows a wound dressing comprising a test
strip (50), base
layer (55), and stitching (21). Top view (C) shows the test strip (50) adhered
to wound dressing
(56).
[00229] Integration of dyed peptidoglycan into a lysozyme responsive testing
strip (FIG. 15).
In some embodiments, a testing strip comprises a Whatman filter 1001/85 that
is cut into 0.5 cm
x 4 cm pieces. 2 p.1 of the quaternary amine trapping solution is pipetted
onto the cellulose filter
1.5 cm beneath the upper end of the stripe. 2 ill of a substrate formulation
containing 4 mg dyed
peptidoglycan in 240 .1 0.5% PEG6000 solution in H20 are pipetted 1 cm above
the lower end
of the stripe. The modified strip is incubated at 90 C for 30 minutes. The
test strip is then ready
to use. Alternatively other dyed lysozyme substrates (e.g. dyed chitosan
derivatives) can be
incorporated into the testing system. In some embodiments, the testing strip
comprises a
substrate spot, a quaternary amino trap, and a cellulose matrix.
[00230] In some embodiments, integration of the lysozyme responsive testing
strip into a
dressing for the online detection of early stage wound infections.
[00231] Liquid transport system from the bottom side of the dressing to the
test strip is
performed via a polypropylene yarn stitched through the layers of the dressing
and the first
water impermeable adhesive layer. While the stitching helps the process, it is
not essential and
the same results are obtained without stitching, albeit more slowly. The
testing strip is
embedded in between of two water impermeable adhesive layers. An evaporating
area is
included in the upper region of the strip. The detection unit releases the
coupled dye in region
'a' which is then trapped in area `b' of the testing stripe and gives a clear
visible signal upon
lysozyme activity.
[00232] Material selection for the test strip: Different cellulose based
materials can be used as
solid matrix for the test stripe. Non-wovens containing a defined amount of
cellulose can
alternatively be used. Schematic representation of the Lysozyme test strip.
Attachment of the
- 41 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
detection system to the dressing (FIG. 15). Base layer contains liquid
transfer system to the
detection unit. Upper view of the combined base layer and detection unit.
[00233] Example 5: Indicator reactions
[00234] FIG. 16 shows examples of indicator reactions include a substrate with
at least two
domains A and B, or A and C, connected by a cleavage site (X), which is
recognized by
enzymes in wound fluid, such as elastase (E or E2). In some embodiments,
peptidoglycan
anchor (S) is attached to an enzyme substrate, requiring digestion or
breakdown of the
peptidoglycan anchor (S) by lysozyme (El) before the cleavage site (X) on the
substrate can be
accessed by an enzyme in the wound fluid. Products (P) of the reactions are
colored, giving rise
to a color change detectable by a user. In example I, upon exposure to
elastase (E) in the wound
fluid, the substrate is cleaved at cleavage site X, releasing MPO substrate
(B), which can react
with MPO in the wound fluid and oxidize the substrate (B) to form a colored
product (P). In
example II, lysozyme (El) breaks down peptidoglycan anchor (S) to expose
cleavage site (X).
Upon exposure to elastase (E2) in the wound fluid, elastase cleaves the
substrate at cleavage site
(X) and releases indole (C), which may be converted to indigo in the present
of oxygen, giving
rise to a color change. In example III, MPO substrate (B) may be used instead
of indole (C) to
yield a colored product (P).
[00235] Example 6: Indicator disk
[00236] FIGS. 10-12 show schematics of indicator inserts or disks. FIG. 10(A)
shows the
top view of a diagnostic insert, comprising a reporter area (60), reaction
area (61), and
evaporation area (62). FIG. 10(B) shows the bottom layer, comprising an
impermeable layer of
plastic film, preferably either white or transparent, with a diameter of about
40 mm. The hole in
the middle allows for liquid transport and has a diameter of about 4 mm. The
bottom layer is
covered with adhesive in the same shape underneath for an exact fixation on a
dressing. FIG.
shows the reaction material comprising an adhesive layer (C) and a reaction
layer (D)
wherein each arm may be a different substrate and/or pH system and where the
arms in each
layer overlap to allow exact fixation. Indicator disks can have any number or
indicator arms,
such as 4 or 5 arms of indicators arranged radially as in FIG. 10. In some
embodiments, the
indicator disks comprise 1 to 10 arms, or preferably 4 or 5 arms. FIG. 10(E)
shows the cover,
which preferably comprises an impermeable white plastic foil with a diameter
of 20 mm. The
outer ring may have an insider diameter of 25 mm and an outer diameter of 31
mm. The top
layer may be covered with adhesive underneath for an exact fixation on the
reaction material.
[00237] In the embodiment shown in FIG. 11, (A) shows the bottom layer,
comprising a
double sided and hydrophobic film (65) with a diameter of 40 mm. A hole cut in
the middle has
a diameter of about 5-6 mm. Reference (66) shows the hydrophobic lanes on non-
woven or
- 42 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
paper, either full sheet or cut out, placed on the adhesive film. Reference
(67) shows traps
printed on non-woven or paper which is adhered to the bottom layer with a back-
flow trap (68).
In (B), the reaction layer comprises arms, each may have a different indicator
and color system
as shown in (70). An evaporation cover (71) may be printed, sprayed, or
overlaid film.
Reference (72) shows the indicator disk affixed to a dressing, wherein outer
dressing has a
window (shown as dashed line) for viewing the indicator change.
[00238] In another embodiment of the indicator disk, as shown in FIG. 12,
bottom layer (A)
preferably comprises a white or transparent impermeable plastic film (73) of
diameter 40 mm.
A hole in the middle of bottom layer, comprising a diameter of 4 mm allows for
wound fluid
transport. The bottom layer may be covered with adhesive in the same shape
(73) as the
reaction material (77) underneath for an exact fixation on wound dressing,
double-sided
adhesive and hydrophobic. The reaction layer (77) is placed on top of adhesive
layer (73), at the
bottom. Each arm of the reaction layer may be 13 mm or 15 mm in length from
the center, and
about 5 mm wide. Cut access in the center of the disk may also comprise a back-
flow trap (75)
to ensure fluid flows from the center outward to evaporation area in the
periphery of the insert.
Reference (74) shows hydrophobic lanes on non-woven or paper, fill sheet or
cut out, placed on
adhesive. Reference (76) shows traps printed on non-woven or paper with back-
flow trap (75)
in the middle. In some embodiments, reaction material (77) comprises brilliant
black print, pH
indicator, MPO substrate, elastase-peptide-indoxyl, and lysozyme-peptidoglycan
indicator, and
any combination thereof on arms of the indicator disk. Such substrates may be
printed on the
reaction material or solid support material. Evaporation cover may be printed,
sprayed, or
overlaid as a film over (78), shown as gray box in (78). The reaction material
may be covered
by a transparent or translucent film, with a window (79, dash-line box) to
allow detection of the
reaction.
[00239] In some embodiments, a cover as shown in FIG. 10(E), comprises a
middle cover of
impermeable white plastic film with a diameter of 20 mm, an outer ring with an
inside diameter
of 25 mm and an outer diameter of 31 mm, and a top layer covered with adhesive
in the same
shape underneath for an exact fixation on the reaction material.
[00240] As shown in FIG. 10(A), one embodiment comprises an impermeable white
plastic
foil with an outer diameter of 31 mm, inner diagnostic circle (60, reporter
area) with diameter of
25 mm, and the substrate cover (61) with diameter of 20 mm in embodiments
using a substrate
cover. Evaporation area (62) is located at the periphery of the indictor
insert. A small
evaporation area, such as 2x5 mm may be too small for a 7-day run, but is
sufficient for a
smaller run, such as a one-day run. Visible signal resulting from reactions
can be detected in
- 43 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
diagnostic area (60) or window reporter area (FIG. 11 or FIG. 12). Such
reporter areas can be
surrounded by an off-white layer to achieve maximum contrast to color signals.
[00241] In another embodiment, the diagnostic reaction can be performed on a
solid phase in
which liquid sample diffuses in the vicinity of dyes that are absorbed onto
the solid phase.
Enzymes carried in the sample can transform the dyes through contact in the
pores of the solid
phase material The changes are visible as color changes. Due to the low
volumes in use and
the high concentration of dye, the color change can be a sensitive indicator.
[00242] In a preferred embodiment indicator disks are prepared by impregnating
a filter paper
with the reagents and then punching disks prior to adhering them to a carrier
to form a "stick"
with a reactive dye coated on to it. This stick can be brought into contact
with the sample and a
color change observed.
[00243] In a more preferred embodiment, more than one indicator disk type is
placed onto the
stick carrier such that multiple enzymes or parameters can be detected in one
test. Parameters
that may be determined include pH, lysozyme, elastase, Cathepsin G, MPO,
catalase and lipases.
Such a stick should also contain a positive control to indicate adequate
sample wetting, and or
sample application including, in addition to wetting, also the presence of
protein.
[00244] In one preferred embodiment the indicator disks are aligned in a line
on a thin "stick"
and the sample is applied to them in sequence using a swab, gauze, or by
pressing the stick into
or onto a sample, for example a used dressing.
[00245] In another embodiment, the indicator disks are aligned next to each
other on a broad
support and their edges on one side are cut such that the stick can be pressed
with the cut edge to
the sample source (i.e. a used dressing or diluted wound fluid, or the edge of
a cleaning swab or
gauze) such that liquid is taken up into each of the disks at the front of the
broad stick ("Fork"
format).
[00246] In another preferred embodiment the indicator disks are placed inside
a carrier box
such that the sample swab can be inserted into the box and then sealed inside
by closing the box.
After closure, the sample swab can be moved and in the process, contacts each
sample disk in
turn to wet them appropriately such that the resulting reaction can be
observed through windows
appropriately placed above each indicator disk. Such an arrangement can
preserve the swab for
later microbiological examination and simplify the handling of materials at or
during a dressing
change.
[00247] Indicator disks are preferably prepared with reagents that are capable
of color
change. Such reagents may be selected from compounds such as p-aminophenol,
ABTS
(2,2inophenol, ABTS (strate. In some embodiments, acid) diammonium salt), 3,3'-
diaminobenzidine, 3,4 diaminobenzoic acid, DCPIP, N,N-dimethyl-p-
phenylenediamine, o-
- 44 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
dianisidine, p-phenylenediamine, 4-chloro-1-naphthol, o-phenylenediamine N-(4-
aminobuty1)-
N-ethylisoluminol, 3-amino-9-ethylcarbazole, 4-aminophthalhydrazide, 5-
aminosalicylic acid,
2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid), indoxyl, indigo, Fast
Blue RR, 4-chloro-
7-nitrobenzofurazan. In some embodiments, the reactive layer comprises an
arylamine. In some
embodiments, the reactive layer comprises an amino phenol. In some
embodiments, the reactive
layer comprises an amino phenol an aminophenol ether. In some embodiments, the
reactive
layer comprises an indoxyl. In some embodiments, the reactive layer comprises
an a neutral dye.
In some embodiments, the reactive layer comprises a charged dye, e.g., a dye
selected from
remazole brilliant blue, toluidine blue, reactive black 5, remazol brilliant
blue, reactive violet 5,
and reactive orange 16, or a hydrolytic or ammonolytic derivatives thereof,
toluidine blue,
reactive black 5, or ahydrolytic or ammonolytic derivatives thereof; reactive
violet 5, or
hydrolytic or ammonolytic derivatives thereof; reactive orange 16, or
hydrolytic or ammonolytic
derivatives thereof; a dichlorotriazine-based reactive dye such as reactive
blue 4, reactive red
120, reactive blue 2, reactive green 19 and reactive brown 10. In some
embodiments, the
dichlorotriazine-based reactive dye appears black. In particular embodiments,
the reactive layer
comprises compounds such as a reactive dye containing a sulfonylethyl-
hydrogensulphate-
reactive-group. In some embodiments, the reactive dye is reactive black 5,
remazol brilliant
blue, reactive violet 5 or reactive orange 16, particularly reactive black 5.
In some embodiments,
the reactive dye is remazol brilliant blue, reactive violet 5, reactive orange
16, reactive black 5,
or remazol brilliant blue. Especially, the reactive layer comprises a dye
containing a
sulfonylethyl-hydrogensulphate-reactive-group, e.g., reactive black 5, remazol
brilliant blue,
reactive violet 5 or reactive orange 16, or a combination thereof; or a dye
containing a
dichlortriazine reactive-group, e.g., reactive blue 4, reactive red 120,
reactive blue 2, reactive
green 19 and reactive brown 10, or a combination thereof.
[00248] In other embodiments, indicator disks are preferably prepared with
reagents that are
capable of physical change, e.g., nanoparticle, colloidal gold particle or a
luminol derivative.
[00249] In a preferred embodiment, MPO is detected using an analog of Fast
Blue, or a di-
amino phenol as a color generating agent; Elastase is detected using a peptide
derived indicator
including a napthol phenol, indoxyl or a nitro-phenol; Lysozyme is detected
using an oligo
saccharide conjugated to a dye or color generator, or an oligosaccharide
particle containing a
charged dye in particular said oligosaccharide may be selected from
peptidoglycan or chitosan
derivatives. Purely as a representative example, lysozyme may be detected by
visualizing
reactive black 5, remazol brilliant blue, reactive violet 5 or reactive orange
16, reactive blue 4,
reactive red 120, reactive blue 2, reactive green 19 and reactive brown 10, or
a combination
thereof bonded to a substrate such as chitosan, N-acetyl chitosan; oligo-I3-D-
1,4-glucosamine;
- 45 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
acetyl-D-glucopyranoside; N-acetylglucosamine (G1cNAc); glucosamine dimer
(G1cNAc)2;
acetyl-chitosan; chitobiose octaacetate; a chitooligomer comprising the
structure (G1cNAc)õ
wherein n=4, 5, or 6; a chitooligosaccharide; 2-acetamido-2-deoxy-D-
glucopyranoside; 2-
deoxy-3,4,6-tri-0-acetyl-D-glucopyranoside; or a combination thereof. Protease
such as human
neutrophil elastase or HNE) may be detected by using a peptide substrate
comprising a core
sequence Alanine-Alanine-Proline-Valine (AAPV) which is conjugated to one or
more of the
aforementioned dyes.
[00250] In another embodiment, the reagents to detect these analytes are
subject to cleavage
to yield a compound that is trapped on an immobile portion.
[00251] Example 7. Use of an indicator dressing in the context of a wound
therapy.
[00252] A dressing containing an indicator disk as described above is
prepared in which the
printed disks are inserted between the absorbative outer layer of the dressing
and the outer
membrane or film such that the reacted areas are visible. The dressing is
applied to a wound, be
it chronic or surgical, such that sites of secretion in the wound (deeper
sites, sutures) are located
under or as near as possible to centers of the disks. See FIG. 17. Following
dressing
application, the dressing will begin to absorb secretions. In one embodiment,
the first
observation of wound status can be made after the "flow control" has turned
blue. This is an
indicator of the fact that sufficient liquid has entered the dressing to
saturate the reagent pads.
If, at this stage one or more of the biomarker indicators has already reacted,
this would be an
indicator of the fact that a degree of inflammation or potential infection was
present in the
wound at dressing change. One biomarker reacting, with or without an
indication of pH above
neutral, is likely sufficient to justify detailed wound hygiene steps at the
next change. Two
biomarkers responding with or without a pH above neutral is likely an
indication that in an ideal
situation, the wound would be immediately re-dressed and anti-microbial
approaches initiated.
Three biomarkers responding, with or without pH would likely be an indicator
that in an ideal
situation the dressing should be immediately changed and anti-microbial
hygiene, wound
dressings and laboratory microbiology should be initiated.
[00253] In a broad sense the indicators can respond immediately after dressing
change, after
1-2 days and after 2-5 days. Due to the dynamics of flow, the reagents are
intended to respond
within 2-6h of exposure to a threshold of enzyme activity, for example 0.5
U/mL elastase,
however, long exposure to low enzyme levels, i.e. 5 days, may also ultimately
engender a signal.
Thus, the user can distinguish a low level of activity from an acute sign in
that the reporter area
very slowly accumulates signal, i.e. very faint at 3 or 4 days and only
slightly more developed
after 4 or 5 days. This would be indicative of a wound deserving of close
observation and
hygiene but not necessarily one in acute infection. Experience with the
particular patient would
- 46 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
also inform the therapist. If the same pattern was apparent over multiple
dressing changes it
would suggest a stable situation but that any change in the degree of reaction
should be taken as
an indication of a potential change in wound status.
[00254] In contrast, a situation in which a strong signal suddenly appears is
potentially
indicative of the onset of an acute infection. Given that the indicator can
change within 1-2
hours once a threshold is crossed suggests that any sudden developments
reflect the current
situation of the wound.
[00255] Where multiple infection indicator disks are placed within the wound
dressing, the
position of those that react is an indicator of where in the wound potential
problems arise. Thus,
the absence of clear signals after 5 days would be an indication that no
thresholds have been
crossed in that period and that current therapy may be adequate. Weak signals
that develop
slowly may indicate that hygiene could be improved. Moderate signals that
appear gradually
after 5 days may be the first signs that an infection is developing and should
result in more
elaborate therapy. Strong signals that develop over 5 days would be
correspondingly more
emphatic indications that therapy need be improved, for example, by
instituting silver dressings.
The rapid onset of a clear signal is, in turn, the indicator of an acute issue
that merits immediate
attention.
[00256] As shown in FIG. 4(C), multiple reaction cells can be applied to a
wound dressing in
some embodiments for detection of microbial infection over an area. Amine back
flow trap or
filter or leach-back trap (41) may be used to separate testing regions.
[00257] Example 8. Dressing inserts that may be applied to any dressing.
[00258] In some embodiments, indicator insert may be freely placed at a site
of likely
secretion or placed anywhere in a wound dressing or a surgical dressing.
[00259] Diagnostic disks, as described above, can be incorporated into a
dressing during its
manufacture. These inserts may be placed between the outer absorbent and the
outer film and
equally spaced, and glued in place during manufacture. However, the fixed
spacing may not be
appropriate to a particular wound. In this example, the reporter disks are
prepared as
independent materials that can be put on any absorbent dressing below the
outer film. For
example, the inserts are prepared as stand-alone disks, cut and sealed in
sterile outer envelope.
Therapists using dressings, see reference (92) in FIG. 17, without reporters
may still insert these
reporters (90) into such dressings in so far as these are modular and require
the therapist to
assemble the dressing from: wound contact material, absorbent, and outer film
or cover. The
reporter disk can fulfill its function in many ways, including so long as it
is in fluid contact with
the wound fluids (91) and otherwise under an appropriate outer dressing. An
adhesive
- 47 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
transparent outer disk is one means of fixing and holding the reporter disk.
Similarly, the disk
itself may have an adhesive bottom coat.
[00260] In another embodiment of diagnostic inserts, shown in FIG. 18, non-
woven layer in a
dressing carries or contains diagnostic disks (705), wherein the dressing
further comprises a film
cover layer (701), non-woven carrier of indicators (702), polyurethane foam
(703), and cellulose
contact layer (704). As demonstrated by the arrow in FIG. 18(A), wound fluid
flows upward to
diagnostic disks (705) embedded in such dressing. FIG. 18(B) shows a side view
of the wound
dressing with embedded diagnostic disks, wherein quaternary amine coating
(shown as dashed
line) on foam surface acts as trap for preventing return of diagnostic
substances and that wound
fluid flows upward to diagnostic disks.
[00261] In a further embodiment of diagnostic disks in wound dressing, as
shown in FIG.
19(A), the side view representation (A) shows an example disk for detecting
MPO, wherein
(720) is a paper disk impregnated with the MPO substrate through dipping or
spray coating.
Reference (721) is the paper or non-woven material that acts as a carrier.
Reference (722)
shows an adhesive layer. Reference (723) represents a disk containing glucose
oxidase and/or
starch and an amylase, such as gamma amylase. FIG. 19(D) shows the wound fluid
mobilizes
starch into glucose, which in turn is oxidized by glucose oxidase to yield
H202. This is used by
MPO in the wound fluid to convert the substrate to the detectable blue form.
FIG. 19(B) shows
the side view of a disk for detecting lysozyme, wherein particles of chitosan
or peptidoglycan
are embedded in the paper disk on its lower side using a water permeable
adhesive layer that
also serves to adhere the disk to the foam layer below. Enzyme activity
dissolves the particles
and releases dye that is trapped and is detectable in the top layer. In FIG.
19(B), the paper disk
(730) is a trap impregnated top layer. In the presence of wound fluid, as
shown by the upward
arrow in FIG. 19(C), the paper/non-woven disk acts as a carrier (721) so that
the wound fluid
moves to the top layer, via stained peptidoglycan particles (731) in the
process. Reference (722)
shows an adhesive layer. Reference (732) shows an adhesive ring or thermal
weld that secures
the disk to the non-woven carrier layer (721). The dashed line in FIG. 19(C)
represents
quaternary amine coating on foam surface under the diagnostic strips that acts
as a trap for
preventing return of diagnostic substances. FIG. 19(E) shows stained
peptidoglycan particles
slowly being dissolved by wound fluid and the dye that is released is then
captured in the trap
material while excess wound fluid flows to the sides, as indicated by the
arrows. In FIG. 19(E),
the paper disk is impregnated with trap material in the top layer.
[00262] In FIG. 20, the scaling up of the production of the disk constructs is
described. In
the continuous process, the disks are punched from a sheet comprised of
sealing film, the
adhesive, the paper or non-woven carrier, which is protected by the top cover
sheet.
- 48 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
[00263] FIG. 21 shows different embodiments of paper disks. FIG. 21(A) shows
the
different layers involved in such embodiments, namely, film cover on top, a
non-woven carrier,
a polyurethane foam, and a cellulose contact layer. FIGS. 21(B) to 21(E) show
different
variants of such analytic system with indicator disks. FIG. 21(B) shows non-
woven carrier of
indicators with diagnostic disks attached, including pH indicator on paper,
paper disk printed
with starch, amylase, and glucose oxidase, and trap impregnated paper disks.
FIG. 21(C) shows
partly printed non-woven and applied paper disks, including trap printed and
UV border or trap
border (910). FIG. 21(D) shows partly printed non-woven and gradient (911)
application of
indicator disks. The gradient is formed by printing concentric rings of
substrate at different
concentration, or with a different pH mediator. Fully transformed, different
substrate
concentrations lead to different color intensity. Alternatively, using
polymeric buffers in each
ring can modulate the degree of reaction requiring more activity to yield the
same color.
Suitable buffers include polycarbonates and polysulfonates. The number of
concentric rings of
color provides an indication of overall activity and thus with reference to a
color chart can assist
in assessing the degree of severity. FIG. 21(E) shows one embodiment of the
diagnostic disks
with printed indicators (912) and reagents applied on adhered paper disks. In
these
embodiments, the non-woven functions as a carrier of indicators.
[00264] FIG. 22 shows different ways diagnostic disks (800) may be attached to
a dressing.
For example, FIG. 22(A) shows continuous adhesive that allows wound fluid to
penetrate
through the adhesive. FIG. 22(B) shows ring or annular adhesive that allows
wound fluid to
penetrate via the hole in the middle of the adhesive layer. FIG. 22(C) shows
welding with UV
printed border. FIG. 22(D) shows welding with polyethylene component of non-
woven.
[00265] Example 9: Dipstick ¨ traffic light format.
[00266] Certain reagents have adequate affinity for paper or similar solid
phases and remain
substrates for the biomarker enzymes of interest. Where these substrates
exhibit color change,
the activity of the enzymes can be observed by simply contacting the fluid
containing the
markers with the impregnated paper. Capillarity ensures the distribution of
the fluid to the
substrate. Each impregnated disk can be separately added to a combined
"dipstick" which
allows all disks to be used in a test (FIG. 23). One format is the linear
array of disks, although
the layout may be easily varied.
[00267] FIG. 23 shows indicator inserts or disks (820) specific for various
enzymes or
microbial biomarkers and controls may be placed in various combinations or
arrangements to
form various dipstick devices. Each impregnated disk (820) can be separately
added to a
combined dipstick that allows all indicator disks to be used in a test. One
format is the linear
- 49 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
array of disks, although the layout may be easily varied. Indicator disks may
be separated by
lanes or borders (821).
[00268] In this example, the following disks are prepared:
[00269] 1. Fluid control: a 5 mm disk of double sided adhesive is punched,
and 50 lig of a
micronized Fast green powder is placed on the adhesive in the center. A paper
disk is placed
over the adhesive disk concentrically, such that the powdered dye is covered
by the paper. The
resulting disk is then placed in the first position on the carrier stick via
the other side of the
adhesive.
[00270] 2. pH control. Filter paper is soaked in a mixture containing
bromothymol blue,
chitosan and glutaraldehyde in ethanol as reported above. The filter paper is
dipped in the
mixture, allowed to drip dry, and is then dried on glass at 54 C. 5 mm disks
are then punched
and the disks are attached to the carrier with adhesive.
[00271] 3. MPO indicator. 5 mm paper disks are impregnated sequentially with
1.5 L of the
MPO fast blue substrate as described above for the Dressing indicator. Once
dried, one half of
the disk is impregnated with 10 [tg of glucose and the other half of the disk
is impregnated with
1 Idg of glucose oxidase in buffer (PBS).
[00272] 4. Elastase indicator. Filter paper was impregnated with a mixture (
0.25 % (w/w)
Nonidet, 2 % (w/w) decanol in 0.05 M borate buffer pH 8) and dried for 1-2 h
at 54 C. 5 mm
paper disks are punched from the buffer treated paper and impregnated
sequentially with 2 times
2.5 1.i.L of the AAPV indoxyl substrate (10[1g/4 in acetone) as described
above for the
Dressing indicator.
[00273] 5. Lysozyme indicator. Filter paper is lightly sprayed (1.5 I, per
cm2) with a trap
solution containing 3% W/V quaternary amine trap and allowed to dry with the
top surface
identified. A 5 mm disk of double sided adhesive is punched, and 40 jig of a
Brilliant Black
stained Peptidoglycan is placed on the adhesive in the center and allowed to
dry. A paper disk is
placed over the adhesive disk concentrically, such that the PG-dye deposit is
covered by the
paper. The resulting disk is then placed in the fifth position on the carrier
stick via the other side
of the adhesive. The resulting dipstick can have the sample applied to it by
means of swab, or
gauze.
[00274] Example 10: Dipstick ¨ "fork" format.
[00275] In one embodiment a dipstick is prepared essentially as for the above
example with
the exception that the reagent disks are oriented to the base of a thicker
carrying card or stick.
The ends of the reagent disks are trimmed at the last stage of production such
that they are flush
with the bottom edge of the device. This allows them to be pressed onto a
surface to be
- 50 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
sampled. The sample then diffuses into the cut end of the disks to react. This
format is
potentially more convenient for sampling surfaces like used dressings.
[00276] Example 11: Dipstick ¨ box format.
[00277] In certain instances, suspected infection, or the risk of
contamination between
patients through consumables and their disposal demands a more secure system.
In one
embodiment, where sampling is done via a swab, retention of the swab for
subsequent
bacteriological evaluation may be desirable. Similarly, it may be desirable to
retain the result
and display it to a colleague after a dressing change. In this context, a
means to retain the result
without risk of contamination is desirable. To this end, in one embodiment, a
sealable container
or enclosure may be used for accommodating a plurality of disks, such as 6
disks, in which a wet
swab can be placed and then closed such that it can apply the sample to the
paper disks but not
contaminate any further objects. One such design is illustrated along with its
working principle
(FIG. 23). The key elements of the design are: the well for wetting the swab;
its closed sealable
form; the sealing rings around the stem of the swab; the pressure fins that
push the swab to the
disks while also making it a one-way movement; the window to the disks; the
space for
reference colors on the case, the possibility to re-open in a microbiology
lab.
[00278] Example 12: Surgical site detection
[00279] In another embodiment, the dressing is intended for the treatment of
surgical wounds
and contains distinct linear regions intended to be placed over the line of
sutures. These linear
regions contain particularly high concentrations of reporter dye such that
even in the earliest
phases of infection, the signal will be apparent. In another embodiment, the
dressing contains a
removable components such as a thread, or similar absorbent that can be
withdrawn and tested
without removing the dressing (FIG. 24). Said removable component is placed in
such a way as
to be located at or near the edges of the surgical wound. In another
embodiment, the surgical
site dressing is essentially transparent in the linear region both to allow
observation of the
sutures, and the reporter dye. In a preferred embodiment, the transparent area
is covered by an
opaque film that may be easily peeled back to examine the wound. In another
embodiment the
covering and absorbent material contains a trapping material such as a
polymeric cation or anion
that is capable of binding and concentrating the dyes that are released.
[00280] For example, in FIG. 24, sampling threads (100) are built in or added
to dressing for
a wound or at a surgical site (92). AQUACEL (4) is used in some embodiments of
the dressing
(92). Sampling threads absorb wound fluid or fluid at surgical site (D). A
thread may be pulled
out or extracted (E) from dressing without having to remove or disturb
dressing using an
instrument or device (101) such as a tweezer, hook, or thread hook device. The
thread can then
- 51 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
be dissolved in a buffer for use in a diagnostic device (102) using one or
more indicator regents
or indicator disks described herein.
[00281] In some embodiments, a wound dressing comprises built in sampling
threads. In
some embodiments, the sampling threads absorb wound fluids and may be removed
without
disturbing the wound dressing for detection of analytes in the wound fluid.
[00282] In some embodiments, the sample threads may be diluted in buffer to
dissolve
markers for diagnosing the status of the surgical site or wound.
[00283] In some embodiments, a thread hook device may be used to remove a
thread from a
wound dressing.
[00284] Example 13: Manufacture of dressing inserts
[00285] The reporter inserts are manufactured by the sequential placement of
various
materials on a solid carrier. This carrier can be a cellulose, viscose,
polyethylene, polyamide or
other suitable polymer or mixture of these components.
[00286] FIG. 25 shows indicator inserts may be manufactured or printed in
sheets or reels.
FIG. 25 also shows the order of printing, printing of lanes, order on which
reagents are laid
down, and placement of reagents for printing disks in sheets or reels,
comprising adhesive or
backing film as in FIG. 25(A), applying a non-woven material as in FIG. 25(B),
and printing
reagents and lanes on non-woven material as in FIG. 25(C). Completed or
assembled inserts, as
show in FIG. 25(D) can be separated or cut before sticking to a dressing or
similar support
materials.
[00287] In one embodiment the material is prepared in a reel to reel format.
The solid carrier
is first printed with guide lanes that penetrate the film to full thickness.
Next, a bottom film that
sits under the polymer and does not penetrate it is printed, this includes a
hole in the center
through which sample fluid enters. Next trap material is printed, at half
density around the
entrance site (back-flow trap) and at full density in the trapping sites for
the flow control and the
lysozyme substrate. Next the flow control ink is applied to the first position
of the radial arms of
the disk, 10 to 50 ug of Brilliant black in 1 % methylcellulose is typical.
Next the pH reporter,
as described above is printed in position 2. Next, the MPO area is printed
sequentially with
substrate, glucose and glucose oxidase as noted above. Next the elastase
substrate is applied in
sequential prints to reach the appropriate load. Next the lysozyme substrate
is printed to
position 5 in the reagent level (as distinct from the trap level). Finally a
film is printed on the
top of the construct but without penetration of the solid carrier. This film
occludes only the
radial arms from center to the end of the reporter window.
- 52 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
[00288] The resulting reel contains a continuous pattern of evenly spaced
reporter fields.
These continuous printed fields can be directly rolled into a dressing
sandwich between
absorbent and outer film, or, they may be punch cut and packaged for separate
use.
[00289] FIG. 20 shows another embodiment of manufacturing paper disks. FIG.
20(A)
shows a side view of a continuous sheet, comprising a cover film on top, paper
in the middle,
and backing film at the bottom. Adhesive/particle matrix (901) may be applied
between the
cover film/backing film and the paper layer (900). FIG. 20(B) shows a top view
of cut sheets
prepared for application to non-woven carrier by removal of inter disk
material prior to
placement on non-woven carrier.
[00290] Example 14: Manufacture of reagents for liquid based devices
[00291] In certain embodiments, it is desirable to place reagents in devices
in such a way as
that they are stable, but readily soluble for access to injected enzymes. One
approach is to dry
reagents on disks of paper and include the disks in the devices.
[00292] Disks are prepared using either a continuous paper or similar material
or textile
which is dipped, sprayed or printed, or using pre-cut disks that are dipped or
mixed in a reagent
and subsequently dried. See FIGS. 20, 25.
[00293] The densities of the reagents per 20 mm2 are:
[00294] MPO substrate (alkyl-fast blue) 0.6 ug
[00295] Glucose 10 ug, glucose oxidase 1 ug
[00296] For elastase, paper is first impregnated with impregnation mixture
(0.25 % (w/w)
Nonidet, 2 % (w/w) decanol in 0.05 M borate buffer pH 8).
[00297] Thereafter the paper is sprayed with a solution of elastase substrate
corresponding to
2.5 ug per mm2.
[00298] The paper so printed can be punched to yield disks containing the
reagents.
[00299] These disks can then be incorporated into the devices.
[00300] Example 15: Manufacture of reagents for liquid based devices
[00301] Alternatively, the reagents may be pressed into water soluble
"pellets" which are then
included in the wells of the devices. The pellets can contain a range of
materials in addition to
those used on paper.
[00302] A liquid based diagnostic device uses pre-formulated reagents to
generate a colour in
response to enzyme activity in a sample. The sample may contain all or only
some of the liquid
required. Where the sample is to be diluted, the device preferably contains
water or buffer
suitable to dilute or render the sample homogeneous. The resulting mixture is
distributed to
wells which each contain a different reagent set. The reagents are a mixture
of buffer salts,
energy source, substrate and associated chromophores if not contained in the
substrate. These
- 53 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
reagents are ideally delivered in a discreet entity like a tablet or similar
that can be placed in the
wells. Here we describe the preparation of tablets for enzymatic assays for
elastase, lysozyme,
MPO and protein standard as internal standard. The tablets dissolve after
addition of wound
fluid and release assay components to start the enzyme reactions that lead to
colour changes
where positive.
[00303] A Perkin Elmer electro-hydraulic tablet press is used to form the
tablets as follows:
[00304] The pressing time per tablet is approximately 10 sec.
[00305] The diameter of the filled part of the pressing tool is 5 mm
[00306] Tablets are: 20 mg, 5mm diameter, 1 mm deep
[00307] A vacuum is first applied for about 15 sec.
[00308] The applied vacuum is maintained until the removal of the pressing
tools.
[00309] The pressing pressure is adjusted to 2 t.
[00310] Table 1: List of tablet reagents for use in liquid-based diagnostic
devices.
Component Amount
in 20 mg
(mg)
MPO Tablet
Na2CO3 0,38
NaHCO3 0,54
Guajacol (CH30)C6H4OH = Substrate 1,53
Alternatively diaminophenol
Sodium percarbonat x 1,5 H202 (Na2CO3-1.5 H202) 0,02
Maltose Monohydrate (C12H22011 = H20) 17,53
Elastase Tablet
Sodium Acetate (C2H3Na02) 1,64
Sodium chloride (NaCl) 5,84
N-Methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide (C 2714381\16 09) = 0,24
Substrate
Maltose Monohydrate (C12H22011 = H20) 12,28
- 54 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
Lysozyme Tablet
Potassium hydrogenphosphate (K2HPO4) 7,32
Potassium dihydrogenphosphate (KH2PO4) 1,09
Peptidoglycan (von Micrococcus lysodeicticus) as a film or dyed with 0,20
reactive black as gross particles=Substrate
Maltose Monohydrate (C12H22011 = H20 ) (Filler) 11,39
Internal Standard Tablet
Citric acid (HOC(COOH)(CH2COOH)2 8,56
Sodium hydrogenphosphat (Na2HPO4) 1,54
Bromophenol blue (Ct9HioBr405S) 0,06
Maltose Monohydrate (C12H22011 = H20) 9,84
[00311] Example 16: Standalone device and kit for liquid based assay
[00312] Stand-alone devices and kit for detecting and measuring wound
infection using the
compositions and device are described herein. These devices and kits
preferably comprise a
sampling component for collecting a sample and a test device. In some
embodiments, the test
device comprises a housing surrounding a tube to define an opening in the
housing to receive the
sampling component, the housing having within it a sealed diluent chamber
which is connected
to an opposite end of the tube and holding a liquid diluent for removing the
sample from the
sampling tip to form a test liquid. The tube is in liquid communication with a
reaction well
which holds a reagent capable of indicating the presence of the analyte. A
driving mechanism
drives the diluent from the chamber past the sampling tip, into the tube and
finally to the
reaction well.
[00313] In some embodiments, the kit for detecting an analyte in a sample
comprises: (i) a
sampling component comprising a sampling tip for collecting the sample and
(ii) a test device,
further comprising: a housing surrounding a tube to define an opening in the
housing to receive
the sampling component, the housing also having disposed within it: a sealed
diluent chamber
connected to the tube and holding a liquid diluent for removing the sample
from the sampling tip
to form a test liquid; a reaction well in liquid communication with the tube,
the reaction well
holding a reagent capable of indicating the presence of the analyte within the
test liquid; and a
driving mechanism capable of driving the diluent through the device from the
chamber, over the
sample tip and into the reaction well.
- 55 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
[00314] The kit operates by driving the diluent over the sample and into a
reaction well, a test
solution is made by the flow of the diluent over the sample. It is not
necessary to first mix the
sample with the diluent to make a test solution and then move that solution
via a lateral flow
strip to the reaction well. The driving of the diluent past the sample and to
the reaction well
means that the kit can be used with a minimum number of steps, for instance
taking the sample,
inserting the sampling component into the housing and activating the driving
mechanism. This
simple procedure minimizes user error and thus minimizes false negative
results and
misdiagnoses.
[00315] The sealed diluent chamber may contain a specified volume of diluent
so that an
expected volume of test solution reaches the reaction well or wells. In
addition the pathway
between the diluent chamber and the reaction well is vented so that trapped
air does not affect
the flow of test solution through the device or prevent the test solution from
reaching the
reaction well.
[00316] The housing preferably has two parts which are capable of moving with
respect to
each other while remaining connected to one another. The action of moving the
parts may
provide the driving mechanism by which diluent is moved through the device.
The diluent can
be driven through the device by compression of the diluent chamber which
forces the diluent
past the sample tip and to the reaction well or wells. The compression of the
diluent chamber
can occur when the parts of the housing are moved with respect to one another
such as by
sliding one part past another.
[00317] In some embodiments, the housing comprises a locking mechanism which
locks the
housing in position once the driving mechanism has been activated and prevents
reuse of the
device. In this way it is immediately apparent that the device has been used
and cannot be used
again. This minimizes false results from, for instance, a device that has been
mistakenly
activated in transit or from reuse of a device whose reagents have been spent.
[00318] In some embodiments, the sampling component preferably comprises a
handle and a
sampling tip, the handle preferably comprising a seal which engages with the
opening in the
housing to seal the tube when the sampling component is fully inserted in the
tube. The seal
generally prevents escape of the sample and diluent from the device reducing
the chance of cross
contamination from the wound fluid. Preferably the seal and tube engage to
lock the sampling
component in the device and prevent removal of the sampling component once it
has been used.
This further reduces the chance of cross contamination from the sampling
component.
[00319] Preferably insertion of the sampling component in the device releases
the seal on the
diluent chamber. Preferably the seal is a ball valve or can be a film or
membrane seal or a duck
bill valve or other non-return valve known in the art which is activated when
the sampling
- 56 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
component is inserted in the device. The sampling component preferably bursts,
punctures or
displaces the seal on the diluent chamber when it is inserted in the device.
[00320] Preferably the tube is the same or similar size to the sampling tip of
the sampling
component so that the act of inserting the sampling tip into the tube causes
it to be scraped along
the walls of the tube aiding the dispersion of the sample in the diluent once
it is released from
the diluent chamber and is flushed through the device. The sizing of the
sampling tip to match
the tube also forces the diluent to be flushed through the tip when the
diluent is driven from the
diluent chamber. Preferably the diluent chamber is shaped like a bellows to
assist in the
compression of the chamber. Alternatively the chamber can be a combination of
a plunger and
tube similar to that found in a syringe or can be a filled flexible sachet
which is compressed by
hand by the user or a balloon which contracts when the seal is released.
[00321] In some embodiments, the kit comprises a sampling component for
collecting a
sample and a test device. The test device comprises a housing surrounding a
tube to define an
opening the housing to receive the sampling component, the housing having
within it a sealed
diluent chamber which is connected to an opposite end of the tube and holding
a liquid diluent
for removing the sample from the sampling tip to forma test liquid. The tube
is in liquid
communication with a reaction well which holds a reagent capable of indicating
the presence of
an analyte.
[00322] A driving mechanism drives the diluent from the chamber past the
sampling tip, into
the tube and finally to the reaction well.
[00323] FIG. 26 shows a cross section of a standalone device kit for detecting
an analyte in a
sample. The sampling component (2) comprises a handle (4) and a sampling tip
(6) in the
process of being inserted into the housing through one end of a tube (10). The
sampling
component (2) has a sealing means (12) which forms a seal with the open end of
the tube (10)
while the sampling tip (6) depresses the ball valve (14) to open the diluent
chamber (16). FIG.
27 shows a sampling tip fully inserted in the housing to seal the component to
the device. FIG.
28 shows a plan view of the standalone device kit with the sampling component
in place and
shows three viewing windows (20) to the left of the housing which coincide
with three reaction
chambers (18) which contain a reagent capable of indicating the presence of an
analyte. The
reaction chambers may contain reagents capable of detecting different analytes
from for instance
a wound fluid. The window on the right of the housing when viewed from above
is a control
window which indicates that the test has taken place. Housing (8) is in two
main parts which are
slidably connected to each other. In FIG. 29, a user of the device can slide a
lower part of the
housing (24) away from the upper part of the housing (26) and in so doing
cause a lever (28) to
compress the diluent chamber (16) and drive the diluent out of the chamber,
through the
- 57 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
sampling tip (6) and up tube (10) to manifold (30). A plan view (FIG. 30) of
the standalone
device kit with housing slid apart, which results in windows (20) and control
window (22)
indicating that a test has taken place. The arrows (A) in FIG. 29 indicate the
movement of the
diluent through the device to form a test solution. Diluent chamber, tube and
reaction chamber
in the standalone device kit are shown in FIG. 31, with the housing removed
for clarity. FIG.
32 shows distribution of test solution to each reaction chamber in a
standalone device kit. Test
solution flows to each reaction chamber (18) from a central node (32). The
node (32) may also
contain a non- return valve to prevent test solution from flowing back into
the device and
causing cross contamination.
[00324] The sampling component comprises a handle and a sampling tip in the
process of
being inserted into the housing through one end of a tube. The sampling
component has a
sealing means which forms a seal with the open end of the tube while the
sampling tip depresses
the ball valve to open the diluent chamber. The sampling tip, when fully
inserted in the housing
to seal the component to the device, allows the housing to be opened,
releasing the diluent and
allowing the forcing means to operate.
[00325] The device also comprises three viewing windows in the housing that
correspond to
three reaction chambers which contain a reagent capable of indicating the
presence of an
analyte. The reaction chambers may contain reagents capable of detecting
different analytes
from for instance a wound fluid. Some embodiments include a control window
which indicates
that the test has taken place and that the sample was sufficient to make the
test viable.
[00326] The user of the device can slide a lower part of the housing away from
the upper part
of the housing and, in so doing, cause a lever to compress the diluent chamber
and drive the
diluent out of the chamber, through the sampling tip and up tube to manifold.
If the device is
not activated, that is if the seal on the diluent chamber has not been broken,
it is not possible for
the housing to open. The opening of the housing causes the viewing windows to
be positioned
over the reaction wells and enable the result to be viewed by the user. This
provides a safety
measure as it ensures that proper operation of the device in order to obtain a
reliable result.
[00327] Once activated, the test solution flows to each reaction chamber from
a central node.
In some embodiments, the node comprises a non-return valve and filter to
prevent test solution
from flowing back into the device and between reaction chambers, which can
cause cross
contamination. The pathway for the flow of diluent through the device is
preferably provided
with vents at the reaction chamber end.
[00328] Example 17. Devices with separate sample preparation chamber
[00329] FIG. 33 shows a diagnostic swab device with housing. In one embodiment
the swab
device comprises a resealable housing (80), further comprising locator and
locking pins (82), a
- 58 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
viewing window (81) for observing visible signals from reagent disks placed in
disk holders
(83), and a groove (85) for placing the swab. Side view of FIG. 33(C) shows
the housing (80).
To use, a user touches a sample with the swab, places the swab in the housing
(80) in groove
(85), pull on the stem of the swab as shown by the arrow in (D) so that the
sample on the swab
slides on the strip (86) and transfers the sample to reagent or indicator
disks (83). The results
may be viewed through viewing window (81). The swab may also be kept in the
housing (80)
for analysis later.
[00330] FIG. 34 shows one embodiment of a thread hook sample preparation
device (200),
comprising a needle-like tip and a handle or plunger (201), wherein the tip
further comprises a
hook for extracting a thread from a dressing without disturbing the dressing
as shown in FIG.
34(A). Upon extracting a thread from the dressing, thread hook device (200)
may be inserted
into a sample preparation chamber or diluent chamber (202) containing a
diluent for dissolving
or diluting microbial biomarkers or wound fluid from the thread FIGS. 34(B)
and 34(C). The
plunger (201) of the thread hook device may be depressed downward in the
sample preparation
chamber (202) so that the tip of the needle breaks a seal as shown in FIG.
34(D) at the bottom of
the sample preparation chamber (203) in order to release the sample solution
into a device for
analysis of wound fluid or surgical site.
[00331] FIG. 35 shows one embodiment of a swab sample preparation device
(300),
comprising a swab (302) with a handle or plunger (301) may be used to touch a
sample for
testing. The swab device (300), after sampling a bodily fluid or wound fluid,
is placed inside a
sample preparation chamber (202) containing a buffer for dissolving or
diluting the wound fluid
or bodily fluid as seen in FIG. 35(A). The swab device is agitated or mixed
inside the sample
preparation chamber to further release the fluid sample into the sample
preparation chamber as
shown in FIG. 35(B). The plunger (301) of the needle is depressed downward as
shown in FIG.
35(C) to break the seal (203) at the bottom of the sample preparation chamber,
allowing the
sample fluid to flow into a reaction chamber containing reagents or indicator
inserts or disks for
detecting microbial infection in the sample taken by the swab. In some
embodiments as shown
in FIG. 35(D), gas is removed using Goretex membranes (204) which are gas and
vapor
permeable, but not permeable to liquid water. Said membranes can be used to
degas both the
sample as it is injected and to vent the fluid chambers where the assay takes
place.
[00332] FIG. 36 shows a sample preparation chamber adapted to indicator
testing. Sample
preparation chamber (202) is adapted for dissolving or diluting a sample for
testing further and
comprises a resealable top (401) and a breakable seal (402) at the bottom of
the chamber (203),
where the sample preparation chamber connects to a reaction chamber or
diagnostic device.
When a swab device or a thread hook device is plunged downward or depressed
downward in
- 59 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
the chamber, it causes the seal (402) at the bottom to break, releasing sample
fluid into a
diagnostic device connected to the chamber.
[00333] In a further embodiment, FIG. 37, a diagnostic device (500) or
analysis system is
adapted to connecting to the sample preparation chamber (202) at one end,
allowing sample
fluid to flow from the sample tip (300) upon breaking the seal (203) at the
chamber connector,
which allows the sample fluid to flow from the sample preparation chamber
(202) into reaction
chambers (502) for analysis. Absorbent material (501) positioned after the
reaction chambers
(502) helps to draw the sample fluid from the sample preparation chamber (202)
into the
reaction chambers (502). Reaction chambers may contain reagents, reagent
tablets, reagent
disks, or indicator inserts, as described herein.
[00334] In so far as liquid phase tests are desired, they may be conducted
using a variety of
means but ultimately rely on the formation of a visible signal in a low volume
of liquid (e.g. 100
?IL). The methods differ in terms of how one acquires, dilutes and introduces
the sample. In
this example, we introduce the sample using an adapted syringe-like
configuration. The sample
may be a swab, piece of gauze or contaminated thread from a dressing. The swab
(FIG. 35) is
placed in a plunger configuration and then the plunger forms a handle with
which the swab can
be mixed with an extraction buffer or a diluent in a sample preparation
chamber. The plunger
then allows the removal of fluid by sealing against the stem of the swab and
the sides of the
chamber simultaneously; a goretex insert in the plunger allows gas removal as
the plunger
descends. Where the sample is a thread or piece of gauze, the swab is replaced
by a hook,
however, the principle is the same as the stem of the hook is placed within
the plunger.
[00335] The sample preparation chamber contains buffer which is mixed with the
sample on
the swab/hook. The chamber is sealed at the Luer-Lock style connector and this
seal is broken
either when the Luer is placed in a receptacle, or when the swab or hook is
pushed through the
bottom of the chamber (FIG. 35). The assay device entrance includes a standard
female Luer
with a Luer lock like surround to ensure good sealing. The modified chamber
engages
irreversibly with the female Luer lock and on depression of the plunger, the
fluid is transferred
gas free into the device via a fluid distribution network. Each chamber in the
device contains a
reagent tablet (see previous example for the reagents). Each chamber is vented
via a goretex
patch sonic welded over the chamber. As soon as the chamber is filled (from
bottom to top),
fluid flow preferably stops. The vented gas passes by a filter before reaching
the atmosphere.
The arrival of fluid dissolves the reagent pills and allows the reaction to
start. The degree of
reaction over a given time is determined by comparison to a chart of colors.
The result is largely
binary, clear color or not. The more markers associated with color, the more
likely the potential
infection. Thus, wound fluids from uninfected wounds do not cause color
change. Those from
- 60 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
infected wounds cause at least one marker to change color and more often all
three markers
within 5 minutes.
[00336] FIG. 38 shows one embodiment of a diagnostic device or a transfer
system,
comprising a chamber or vessel (601) containing a buffer, such as saline, a
resealable top (600),
a plunger or similar device (602) with a gas outlet and a hook or sample tip
at one end for
transferring sample into the a sample preparation chamber or a diluent chamber
(601), and at
least one reaction chamber (606) capable of analyzing a sample fluid from the
chamber (601).
To conduct such analysis, the plunger or piston (602) containing a sample at
the end is inserted
into the sample preparation chamber (601), or a sample is placed in the
diluent chamber (601),
so that the sample may be diluted or dissolved in the buffer in the chamber
(601). The assembly
of a plunger (602) inserted in a diluent chamber (601) is shown in (607).
[00337] The chamber (601) may further comprise a Luer-Lock or slip tip (605)
for connecting
to a reaction chamber (604) or an analysis system. After connecting plunger
unit (601, 602) to
reaction chamber (604), one may depress the plunger (602) downward to break a
seal at the end
of the chamber (601), releasing sample fluid from the sample preparation
chamber into reaction
chambers (604), wherein individual reaction chamber (606) may have a different
reporter or
color system for detecting an analyte. The plunger (602) can further comprise
membrane that
pushes water and lets out gas, thus degassing the sample fluid as one
depresses the plunger into
the chamber. The reaction chambers may be filled in parallel, and the last
chamber contains an
aerosol filter and a pressure exit to atmosphere. Pressure, equalization,
reaction chamber filling
and aerosol filtering can be achieved through membrane exits. In some
embodiments, reaction
chambers contain reagent tablets or reagent disks. Top membranes can be welded
in place using
ultrasound. Lenses that enlarge the view of the reaction chambers are used in
some
embodiments. The connection to the reaction chamber or transfer system (604)
includes a rough
filter and a penetrator for breaking the buffer seal on connection at 605.
Reaction chambers can
be closed at the top and bottom by clipping on.
[00338] The conformation of the reaction vessels can be flexibly organized.
One example is
shown in FIG. 39, which shows another embodiment of an analysis system (604).
Reaction
chambers (606) can be arranged in a radial manner instead of in a linear
arrangement. A fan- or
radial-shaped analysis system (604) is adapted to use with a sample
preparation chamber (601)
with a plunger (602) system for driving a sample solution into reaction wells
or chambers.
Different views of such analysis system (604) are shown in (B). (608) shows a
top view of a
series of reaction chambers arranged in a radial arrangement. In some
embodiments, the
reaction chamber unit (610) may be removable from housing (609). This
removable feature
- 61 -
CA 03019558 2018-09-28
WO 2017/173069 PCT/US2017/024991
facilitates a user in refilling, inserting, or exchanging reagents in
individual reaction chambers
within the reaction unit (610).
[00339] In this example, the reagents used are water soluble and are
formulated as tablets
using excipients such as PEG, maltose and sorbitol as carriers. The tablets
are formulated with
the appropriate amounts of buffer salts in the bulk mixture to result in
optimal pH upon
dissolution. For supply of hydrogen peroxide, sodium percarbonate is used. As
an MPO
substrate, a soluble Fast Blue derivative, i.e the product of reaction with
succinic anhydrice, is
used, alternatively, guacol, diamino phenol or similar may be used. For
Elastase, AAPV
nitrophenol amide is employed, alternatively, AAPV-indoxyl with a diazonium
salt enhancer.
For Lysozyme, the substrate is a labelled peptidoglycan particle, however, the
well contains a
positively charged membrane at the viewing interface. This membrane is derived
on one half
with the trap, and the contrast between the two sides in the main indicator of
reaction indicates
the degree of reaction.
[00340] In some embodiments, such as FIG. 24, sampling threads (100) are built
in or added
to dressing for a wound or at a surgical site (92). AQUACEL (4) is used in
some embodiments
of the dressing (92). Sampling threads absorb wound fluid or fluid at surgical
site (D). A thread
may be pulled out or extracted as shown in FIG. 24(E) from dressing without
having to remove
or disturb dressing using an instrument (101) such as a tweezer, hook, or
thread hook device.
The thread can then be dissolved in a buffer for use in a diagnostic device
(102) using one or
more indicator regents or indicator disks described herein.
[00341] In some embodiments, a wound dressing comprises built in sampling
threads. In
some embodiments, the sampling threads absorb wound fluids and may be removed
without
disturbing the wound dressing for detection of analytes in the wound fluid.
[00342] In some embodiments, the sample threads may be diluted in buffer to
dissolve
markers for diagnosing the status of the surgical site or wound.
[00343] In some embodiments, a thread hook device may be used to remove a
thread from a
wound dressing.
[00344] While preferred embodiments of the disclosed technology have been
shown and
described herein, it will be obvious to those skilled in the art that such
embodiments are
provided by way of example only. Numerous variations, changes, and
substitutions will now
occur to those skilled in the art without departing from the disclosed
technology. It should be
understood that various alternatives to the embodiments of the disclosed
technology described
herein may be employed in practicing the disclosed technology. It is intended
that the following
claims define the scope of the disclosed technology and that methods and
structures within the
scope of these claims and their equivalents be covered thereby.
- 62 -
